Main Menu

Publications Highlights View all by category

Types of Publications


Journal Articles

Choueiri, T.K. Donahue, A.C. Braun, D.A. Rini, B.I. Powles, T. Haanen, J.B. Larkin, J. Mu, X.J. Pu, J. Teresi, R.E. di Pietro, A. Robbins, P.B. Motzer, R.J. (2024). Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma. Cancer discov, Vol.14 (3), pp. 406-423.  show abstract

Larkin, J. Del Vecchio, M. Mandalá, M. Gogas, H. Arance Fernandez, A.M. Dalle, S. Cowey, C.L. Schenker, M. Grob, J.-. Chiarion-Sileni, V. Marquez-Rodas, I. Butler, M.O. Di Giacomo, A.M. Middleton, M.R. Lutzky, J. de la Cruz-Merino, L. Arenberger, P. Atkinson, V. Hill, A.G. Fecher, L.A. Millward, M. Nathan, P.D. Khushalani, N.I. Queirolo, P. Ritchings, C. Lobo, M. Askelson, M. Tang, H. Dolfi, S. Ascierto, P.A. Weber, J. (2023). Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238. Clin cancer res, Vol.29 (17), pp. 3352-3361.  show abstract  full text

Knill, A.K. Blackledge, M.D. Curcean, A. Larkin, J. Turajlic, S. Riddell, A. Koh, D.M. Messiou, C. Winfield, J.M. (2023). Optimisation of b-values for the accurate estimation of the apparent diffusion coefficient (ADC) in whole-body diffusion-weighted MRI in patients with metastatic melanoma. Eur radiol, Vol.33 (2), pp. 863-871.  show abstract  full text

Spain, L. Coulton, A. Lobon, I. Rowan, A. Schnidrig, D. Shepherd, S.T. Shum, B. Byrne, F. Goicoechea, M. Piperni, E. Au, L. Edmonds, K. Carlyle, E. Hunter, N. Renn, A. Messiou, C. Hughes, P. Nobbs, J. Foijer, F. van den Bos, H. Wardenaar, R. Spierings, D.C. Spencer, C. Schmitt, A.M. Tippu, Z. Lingard, K. Grostate, L. Peat, K. Kelly, K. Sarker, S. Vaughan, S. Mangwende, M. Terry, L. Kelly, D. Biano, J. Murra, A. Korteweg, J. Lewis, C. O'Flaherty, M. Cattin, A.-. Emmerich, M. Gerard, C.L. Pallikonda, H.A. Lynch, J. Mason, R. Rogiers, A. Xu, H. Huebner, A. McGranahan, N. Al Bakir, M. Murai, J. Naceur-Lombardelli, C. Borg, E. Mitchison, M. Moore, D.A. Falzon, M. Proctor, I. Stamp, G.W. Nye, E.L. Young, K. Furness, A.J. Pickering, L. Stewart, R. Mahadeva, U. Green, A. Larkin, J. Litchfield, K. Swanton, C. Jamal-Hanjani, M. PEACE Consortium, Turajlic, S. (2023). Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways. Cancer discov, Vol.13 (6), pp. 1364-1385.  show abstract  full text

Brown, J.E. Royle, K.-. Gregory, W. Ralph, C. Maraveyas, A. Din, O. Eisen, T. Nathan, P. Powles, T. Griffiths, R. Jones, R. Vasudev, N. Wheater, M. Hamid, A. Waddell, T. McMenemin, R. Patel, P. Larkin, J. Faust, G. Martin, A. Swain, J. Bestall, J. McCabe, C. Meads, D. Goh, V. Min Wah, T. Brown, J. Hewison, J. Selby, P. Collinson, F. STAR Investigators, (2023). Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Lancet oncol, Vol.24 (3), pp. 213-227.  show abstract

Ng, K.W. Boumelha, J. Enfield, K.S. Almagro, J. Cha, H. Pich, O. Karasaki, T. Moore, D.A. Salgado, R. Sivakumar, M. Young, G. Molina-Arcas, M. de Carné Trécesson, S. Anastasiou, P. Fendler, A. Au, L. Shepherd, S.T. Martínez-Ruiz, C. Puttick, C. Black, J.R. Watkins, T.B. Kim, H. Shim, S. Faulkner, N. Attig, J. Veeriah, S. Magno, N. Ward, S. Frankell, A.M. Al Bakir, M. Lim, E.L. Hill, M.S. Wilson, G.A. Cook, D.E. Birkbak, N.J. Behrens, A. Yousaf, N. Popat, S. Hackshaw, A. TRACERx Consortium, CAPTURE Consortium, Hiley, C.T. Litchfield, K. McGranahan, N. Jamal-Hanjani, M. Larkin, J. Lee, S.-. Turajlic, S. Swanton, C. Downward, J. Kassiotis, G. (2023). Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature, Vol.616 (7957), pp. 563-573.  show abstract  full text

Schmitt, A.M. Larkin, J. (2023). How have immune checkpoint inhibitors transformed melanoma treatment?. Trends in urology & men's health, Vol.14 (3), pp. 26-30.  show abstract

Larkin, J. Oya, M. Martignoni, M. Thistlethwaite, F. Nathan, P. Ornstein, M.C. Powles, T. Beckermann, K.E. Balar, A.V. McDermott, D. Gupta, S. Philips, G.K. Gordon, M.S. Uemura, H. Tomita, Y. Wang, J. Michelon, E. di Pietro, A. Choueiri, T.K. (2023). Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial. Oncologist, Vol.28 (4), pp. 333-340.  show abstract  full text

Haanen, J.B. Larkin, J. Choueiri, T.K. Albiges, L. Rini, B.I. Atkins, M.B. Schmidinger, M. Penkov, K. Michelon, E. Wang, J. Mariani, M. di Pietro, A. Motzer, R.J. (2023). Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. Esmo open, Vol.8 (3), p. 101210.  show abstract  full text

Rasco, D.W. Medina, T. Corrie, P. Pavlick, A.C. Middleton, M.R. Lorigan, P. Hebert, C. Plummer, R. Larkin, J. Agarwala, S.S. Daud, A.I. Qiu, J. Bozon, V. Kneissl, M. Barry, E. Olszanski, A.J. (2023). Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. Cancer chemother pharmacol, Vol.92 (1), pp. 15-28.  show abstract  full text

Manacorda, S. Carmena, M.D. Malone, C. Linh Le, H.M. Furness, A.J. Larkin, J. Schmitt, A.M. (2023). Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids. Eur j cancer, Vol.188, pp. 98-107.  show abstract

Wu, M.Y. Shepherd, S.T. Fendler, A. Carr, E.J. Au, L. Harvey, R. Dowgier, G. Hobbs, A. Herman, L.S. Ragno, M. Adams, L. Schmitt, A.M. Tippu, Z. Shum, B. Farag, S. Rogiers, A. O'Reilly, N. Bawumia, P. Smith, C. Carlyle, E. Edmonds, K. Del Rosario, L. Lingard, K. Mangwende, M. Holt, L. Ahmod, H. Korteweg, J. Foley, T. Barber, T. Hepworth, S. Emslie-Henry, A. Caulfield-Lynch, N. Byrne, F. Deng, D. Williams, B. Brown, M. Caidan, S. Gavrielides, M. MacRae, J.I. Kelly, G. Peat, K. Kelly, D. Murra, A. Kelly, K. O'Flaherty, M. Popat, S. Yousaf, N. Jhanji, S. Tatham, K. Cunningham, D. Van As, N. Young, K. Furness, A.J. Pickering, L. Beale, R. Swanton, C. Gandhi, S. Gamblin, S. Bauer, D.L. Kassiotis, G. Howell, M. Walker, S. Nicholson, E. Larkin, J. Wall, E.C. Turajlic, S. CAPTURE consortium, (2023). Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer. Cancer cell, Vol.41 (5), pp. 821-823.  show abstract  full text

Kennedy, O.J. Kicinski, M. Valpione, S. Gandini, S. Suciu, S. Blank, C.U. Long, G.V. Atkinson, V.G. Dalle, S. Haydon, A.M. Meshcheryakov, A. Khattak, A. Carlino, M.S. Sandhu, S. Larkin, J. Puig, S. Ascierto, P.A. Rutkowski, P. Schadendorf, D. Boers-Sonderen, M. Di Giacomo, A.M. van den Eertwegh, A.J. Grob, J.-. Gutzmer, R. Jamal, R. van Akkooi, A.C. Robert, C. Eggermont, A.M. Lorigan, P. Mandala, M. (2023). Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur j cancer, Vol.189, p. 112900.  show abstract

Suárez, C. Larkin, J.M. Patel, P. Valderrama, B.P. Rodriguez-Vida, A. Glen, H. Thistlethwaite, F. Ralph, C. Srinivasan, G. Mendez-Vidal, M.J. Hartmaier, R. Markovets, A. Prendergast, A. Szabados, B. Mousa, K. Powles, T. (2023). Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO). J clin oncol, Vol.41 (14), pp. 2493-2502.  show abstract

Dummer, R. Corrie, P. Gutzmer, R. Meniawy, T.M. Del Vecchio, M. Lebbé, C. Guida, M. Dutriaux, C. Dreno, B. Meyer, N. Ferrucci, P.F. Dalle, S. Khattak, M.A. Grob, J.-. Briscoe, K. Larkin, J. Mansard, S. Lesimple, T. Guidoboni, M. Sabatini, S. Richtig, E. Herbst, R. Lobo, M. Askelson, M. Ascierto, P.A. Maio, M. (2023). First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401. J clin oncol, Vol.41 (23), pp. 3917-3929.  show abstract

Campbell, K.M. Amouzgar, M. Pfeiffer, S.M. Howes, T.R. Medina, E. Travers, M. Steiner, G. Weber, J.S. Wolchok, J.D. Larkin, J. Hodi, F.S. Boffo, S. Salvador, L. Tenney, D. Tang, T. Thompson, M.A. Spencer, C.N. Wells, D.K. Ribas, A. (2023). Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. Cancer cell, Vol.41 (4), pp. 791-806.e4.  show abstract  full text

Orton, M.R. Hann, E. Doran, S.J. Shepherd, S.T. Ap Dafydd, D. Spencer, C.E. López, J.I. Albarrán-Artahona, V. Comito, F. Warren, H. Shur, J. Messiou, C. Larkin, J. Turajlic, S. TRACERx Renal Consortium, Koh, D.-. (2023). Interpretability of radiomics models is improved when using feature group selection strategies for predicting molecular and clinical targets in clear-cell renal cell carcinoma: insights from the TRACERx Renal study. Cancer imaging, Vol.23 (1), p. 76.  show abstract  full text

Ascierto, P.A. Lipson, E.J. Dummer, R. Larkin, J. Long, G.V. Sanborn, R.E. Chiarion-Sileni, V. Dréno, B. Dalle, S. Schadendorf, D. Callahan, M.K. Nyakas, M. Atkinson, V. Gomez-Roca, C.A. Yamazaki, N. Tawbi, H.A. Sarkis, N. Warad, D. Dolfi, S. Mitra, P. Suryawanshi, S. Grob, J.-. (2023). Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. J clin oncol, Vol.41 (15), pp. 2724-2735.  show abstract  full text

Robert, C. Carlino, M.S. McNeil, C. Ribas, A. Grob, J.-. Schachter, J. Nyakas, M. Kee, D. Petrella, T.M. Blaustein, A. Lotem, M. Arance, A. Daud, A.I. Hamid, O. Larkin, J. Anderson, J. Krepler, C. Grebennik, D. Long, G.V. (2023). Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. J clin oncol, Vol.41 (24), pp. 3998-4003.  show abstract

Diab, A. Gogas, H. Sandhu, S. Long, G.V. Ascierto, P.A. Larkin, J. Sznol, M. Franke, F. Ciuleanu, T.E. Pereira, C. Muñoz Couselo, E. Bronzon Damian, F. Schenker, M. Perfetti, A. Lebbe, C. Quéreux, G. Meier, F. Curti, B.D. Rojas, C. Arriaga, Y. Yang, H. Zhou, M. Ravimohan, S. Statkevich, P. Tagliaferri, M.A. Khushalani, N.I. (2023). Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results. J clin oncol, Vol.41 (30), pp. 4756-4767.  show abstract  full text

Spooner, M. Larkin, J. Liew, S.C. Jaafar, M.H. McConkey, S. Pawlikowska, T. (2023). "Tell me what is 'better'!" How medical students experience feedback, through the lens of self-regulatory learning. Bmc med educ, Vol.23 (1), p. 895.  show abstract  full text

Oza, B. Eisen, T. Frangou, E. Stewart, G.D. Bex, A. Ritchie, A.W. Kaplan, R. Smith, B. Davis, I.D. Stockler, M.R. Albiges, L. Escudier, B. Larkin, J. Joniau, S. Hancock, B. Hermann, G.G. Bellmunt, J. Parmar, M.K. Royston, P. Meade, A. (2022). External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. J clin oncol, Vol.40 (16), pp. 1772-1782.  show abstract  full text

Fu, X. Zhao, Y. Lopez, J.I. Rowan, A. Au, L. Fendler, A. Hazell, S. Xu, H. Horswell, S. Shepherd, S.T. Spencer, C.E. Spain, L. Byrne, F. Stamp, G. O'Brien, T. Nicol, D. Augustine, M. Chandra, A. Rudman, S. Toncheva, A. Furness, A.J. Pickering, L. Kumar, S. Koh, D.-. Messiou, C. Dafydd, D.A. Orton, M.R. Doran, S.J. Larkin, J. Swanton, C. Sahai, E. Litchfield, K. Turajlic, S. TRACERx Renal Consortium, Bates, P.A. (2022). Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. Nat ecol evol, Vol.6 (1), pp. 88-102.  show abstract  full text

Pires da Silva, I. Ahmed, T. McQuade, J.L. Nebhan, C.A. Park, J.J. Versluis, J.M. Serra-Bellver, P. Khan, Y. Slattery, T. Oberoi, H.K. Ugurel, S. Haydu, L.E. Herbst, R. Utikal, J. Pföhler, C. Terheyden, P. Weichenthal, M. Gutzmer, R. Mohr, P. Rai, R. Smith, J.L. Scolyer, R.A. Arance, A.M. Pickering, L. Larkin, J. Lorigan, P. Blank, C.U. Schadendorf, D. Davies, M.A. Carlino, M.S. Johnson, D.B. Long, G.V. Lo, S.N. Menzies, A.M. (2022). Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. J clin oncol, Vol.40 (10), pp. 1068-1080.  show abstract

Schmitt, A.M. Dumas, L. Larkin, J. (2022). Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma. Expert rev anticancer ther, Vol.22 (1), pp. 17-25.  show abstract

Smith, J.L. Menzies, A.M. Cohen, J.V. Mut-Lloret, M. Ozgun, A. Spain, L. Park, J. Quach, H.T. Pallan, L. McQuade, J. Feng, S. Sandhu, S. Atkinson, V. Tsai, K. Long, G.V. Larkin, J. Eroglu, Z. Johnson, D.B. Sullivan, R. Herkes, G.K. Henderson, A. Carlino, M.S. (2022). Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series. Melanoma res, Vol.32 (6), pp. 451-459.  show abstract

Larkin, J. Walsh, B. Moriarty, F. Clyne, B. Harrington, P. Smith, S.M. (2022). What is the impact of multimorbidity on out-of-pocket healthcare expenditure among community-dwelling older adults in Ireland? A cross-sectional study. Bmj open, Vol.12 (9), p. e060502.  show abstract

Shum, B. Larkin, J. Turajlic, S. (2022). Predictive biomarkers for response to immune checkpoint inhibition. Semin cancer biol, Vol.79, pp. 4-17.  show abstract

Giles, R. Maskens, D. Bick, R. Martinez, R. Packer, M. Heng, D. Larkin, J. Bex, A. Jewett, M. Jonasch, E. MacLennan, S. (2022). Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries. Eur urol open sci, Vol.37, pp. 3-6.  show abstract  full text

Kennedy, O.J. Kicinski, M. Valpione, S. Gandini, S. Suciu, S. Blank, C.U. Long, G.V. Atkinson, V.G. Dalle, S. Haydon, A.M. Meshcheryakov, A. Khattak, A. Carlino, M.S. Sandhu, S. Larkin, J. Puig, S. Ascierto, P.A. Rutkowski, P. Schadendorf, D. Koornstra, R. Hernandez-Aya, L. Di Giacomo, A.M. van den Eertwegh, A.J. Grob, J.-. Gutzmer, R. Jamal, R. van Akkooi, A.C. Robert, C. Eggermont, A.M. Lorigan, P. Mandala, M. (2022). Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur j cancer, Vol.165, pp. 97-112.  show abstract  full text

Homicsko, K. Dummer, R. Hoeller, C. Wolchok, J.D. Hodi, F.S. Larkin, J. Ascierto, P.A. Atkinson, V. Robert, C. Postow, M.A. Re, S. Paulucci, D. Dobler, D. Michielin, O. (2022). Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. Cancers (basel), Vol.14 (9).  show abstract  full text

Larkin, J. Pericin, I. Osborne, B. Dodd, P. Collins, C. (2022). Cross-sectional analysis of coding, patient characteristics, consultation frequency and pharmacological treatment of adults with severe mental disorders in Irish general practice. Ir j med sci, Vol.191 (4), pp. 1785-1793.  show abstract

Pericin, I. Larkin, J. Collins, C. (2022). Diagnostic coding of chronic physical conditions in Irish general practice. Ir j med sci, Vol.191 (4), pp. 1693-1699.  show abstract

Larkin, J. Weber, J. Del Vecchio, M. Gogas, H. Arance, A.M. Dalle, S. Cowey, C.L. Schenker, M. Grob, J.-. Chiarion-Sileni, V. Márquez-Rodas, I. Butler, M.O. Di Giacomo, A.M. Middleton, M.R. De la Cruz-Merino, L. Arenberger, P. Atkinson, V. Hill, A. Fecher, L.A. Millward, M. Khushalani, N.I. Queirolo, P. Long, G.V. Lobo, M. Askelson, M. Ascierto, P.A. Mandalá, M. (2022). Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. Eur j cancer, Vol.173, pp. 285-296.  show abstract  full text

Alexander, J.L. Ibraheim, H. Richards, C. Shum, B. Pavlidis, P. Hunter, N. Teare, J.P. Wotherspoon, A. Furness, A. Turajlic, S. Pickering, L. Larkin, J. Speight, A. Papa, S. Powell, N. (2022). Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis. J immunother cancer, Vol.10 (9).  show abstract  full text

Atkins, M.B. Abu-Sbeih, H. Ascierto, P.A. Bishop, M.R. Chen, D.S. Dhodapkar, M. Emens, L.A. Ernstoff, M.S. Ferris, R.L. Greten, T.F. Gulley, J.L. Herbst, R.S. Humphrey, R.W. Larkin, J. Margolin, K.A. Mazzarella, L. Ramalingam, S.S. Regan, M.M. Rini, B.I. Sznol, M. (2022). Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). J immunother cancer, Vol.10 (9).  show abstract

Wolchok, J.D. Chiarion-Sileni, V. Gonzalez, R. Grob, J.-. Rutkowski, P. Lao, C.D. Cowey, C.L. Schadendorf, D. Wagstaff, J. Dummer, R. Ferrucci, P.F. Smylie, M. Butler, M.O. Hill, A. Márquez-Rodas, I. Haanen, J.B. Guidoboni, M. Maio, M. Schöffski, P. Carlino, M.S. Lebbé, C. McArthur, G. Ascierto, P.A. Daniels, G.A. Long, G.V. Bas, T. Ritchings, C. Larkin, J. Hodi, F.S. (2022). Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J clin oncol, Vol.40 (2), pp. 127-137.  show abstract  full text

Rini, B.I. Moslehi, J.J. Bonaca, M. Schmidinger, M. Albiges, L. Choueiri, T.K. Motzer, R.J. Atkins, M.B. Haanen, J. Mariani, M. Wang, J. Hariharan, S. Larkin, J. (2022). Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. J clin oncol, Vol.40 (17), pp. 1929-1938.  show abstract  full text

Clyne, B. O'Neill, S.M. Nuzum, D. O'Neill, M. Larkin, J. Ryan, M. Smith, S.M. (2022). Patients' spirituality perspectives at the end of life: a qualitative evidence synthesis. Bmj support palliat care, Vol.12 (e4), pp. e550-e561.  show abstract

Larkin, J. Moriarty, F. McGuinness, S. Finucane, K. Fitzgerald, K. Smith, S.M. O'Mahony, J.F. (2022). Variation of prescription drug prices in community pharmacies: A national cross-sectional study. Res social adm pharm, Vol.18 (10), pp. 3736-3743.  show abstract

Tomita, Y. Larkin, J. Venugopal, B. Haanen, J. Kanayama, H. Eto, M. Grimm, M.-. Fujii, Y. Umeyama, Y. Huang, B. Mariani, M. di Pietro, A. Choueiri, T.K. (2022). Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101. Esmo open, Vol.7 (5), p. 100564.  show abstract  full text

Serra-Bellver, P. Versluis, J.M. Oberoi, H.K. Zhou, C. Slattery, T.D. Khan, Y. Patrinely, J.R. Pires da Silva, I. Martínez-Vila, C. Cook, N. Graham, D.M. Carlino, M.S. Menzies, A.M. Arance, A.M. Johnson, D.B. Long, G.V. Pickering, L. Larkin, J.M. Blank, C.U. Lorigan, P. (2022). Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. Eur j cancer, Vol.176, pp. 121-132.  show abstract

Schmitt, A.M. Larkin, J. (2022). Symptomatic melanoma CNS metastases in the TRICOTEL study. Lancet oncol, Vol.23 (11), p. e481.

Haanen, J. Obeid, M. Spain, L. Carbonnel, F. Wang, Y. Robert, C. Lyon, A.R. Wick, W. Kostine, M. Peters, S. Jordan, K. Larkin, J. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, (2022). Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann oncol, Vol.33 (12), pp. 1217-1238.

Chesney, J. Lewis, K.D. Kluger, H. Hamid, O. Whitman, E. Thomas, S. Wermke, M. Cusnir, M. Domingo-Musibay, E. Phan, G.Q. Kirkwood, J.M. Hassel, J.C. Orloff, M. Larkin, J. Weber, J. Furness, A.J. Khushalani, N.I. Medina, T. Egger, M.E. Graf Finckenstein, F. Jagasia, M. Hari, P. Sulur, G. Shi, W. Wu, X. Sarnaik, A. (2022). Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J immunother cancer, Vol.10 (12).  show abstract  full text

Bilen, M.A. Rini, B.I. Voss, M.H. Larkin, J. Haanen, J.B. Albiges, L. Pagliaro, L.C. Voog, E.G. Lam, E.T. Kislov, N. McGregor, B.A. Lalani, A.-. Huang, B. di Pietro, A. Krulewicz, S. Robbins, P.B. Choueiri, T.K. (2022). Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. Clin cancer res, Vol.28 (4), pp. 738-747.  show abstract  full text

Collins, C. Pericin, I. Larkin, J. Diaz, E. (2022). Self-rated health and quality of life among Syrian refugees in Ireland - data from a cross-sectional study. Bmc public health, Vol.22 (1), p. 1202.  show abstract

Fendler, A. Shepherd, S.T. Au, L. Wu, M. Harvey, R. Wilkinson, K.A. Schmitt, A.M. Tippu, Z. Shum, B. Farag, S. Rogiers, A. Carlyle, E. Edmonds, K. Del Rosario, L. Lingard, K. Mangwende, M. Holt, L. Ahmod, H. Korteweg, J. Foley, T. Barber, T. Emslie-Henry, A. Caulfield-Lynch, N. Byrne, F. Deng, D. Kjaer, S. Song, O.-. Queval, C.J. Kavanagh, C. Wall, E.C. Carr, E.J. Caidan, S. Gavrielides, M. MacRae, J.I. Kelly, G. Peat, K. Kelly, D. Murra, A. Kelly, K. O'Flaherty, M. Shea, R.L. Gardner, G. Murray, D. Popat, S. Yousaf, N. Jhanji, S. Tatham, K. Cunningham, D. Van As, N. Young, K. Furness, A.J. Pickering, L. Beale, R. Swanton, C. Gandhi, S. Gamblin, S. Bauer, D.L. Kassiotis, G. Howell, M. Nicholson, E. Walker, S. Wilkinson, R.J. Larkin, J. Turajlic, S. (2022). Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer. Cell rep med, Vol.3 (10), p. 100781.  show abstract  full text

Au, L. Larkin, J. Turajlic, S. (2022). Relatlimab and nivolumab in the treatment of melanoma. Cell, Vol.185 (26), pp. 4866-4869.  show abstract

Andres, M.S. Ramalingam, S. Rosen, S.D. Baksi, J. Khattar, R. Kirichenko, Y. Young, K. Yousaf, N. Okines, A. Huddart, R. Harrington, K. Furness, A.J. Turajlic, S. Pickering, L. Popat, S. Larkin, J. Lyon, A.R. (2022). The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment : Including myocarditis and the new entity of non inflammatory left ventricular dysfunction. Cardiooncology, Vol.8 (1), p. 21.  show abstract  full text

Yngvadottir, B. Andreou, A. Bassaganyas, L. Larionov, A. Cornish, A.J. Chubb, D. Saunders, C.N. Smith, P.S. Zhang, H. Cole, Y. Research Consortium, G.E. Larkin, J. Browning, L. Turajlic, S. Litchfield, K. Houlston, R.S. Maher, E.R. (2022). Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases. Hum mol genet, Vol.31 (17), pp. 3001-3011.  show abstract  full text

Bauer, S. Larkin, J. Hodi, F.S. Stephen, F. Kapiteijn, E.H. Schwartz, G.K. Calvo, E. Yerramilli-Rao, P. Piperno-Neumann, S. Carvajal, R.D. (2022). A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma. Front oncol, Vol.12, p. 975642.  show abstract  full text

Lee, C.-. Motzer, R.J. Glen, H. Michaelson, M.D. Larkin, J. Minoshima, Y. Kanekiyo, M. Ikezawa, H. Sachdev, P. Dutcus, C.E. Funahashi, Y. Voss, M.H. (2021). Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. Br j cancer, Vol.124 (1), pp. 237-246.  show abstract  full text

Olofsson Bagge, R. Ny, L. Ascierto, P.A. Hodi, F.S. Larkin, J. Robert, C. Schachter, J. Weber, J.S. Long, G.V. van Akkooi, A.C. (2021). The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. Melanoma res, Vol.31 (2), pp. 181-185.  show abstract

Siddiqui, M.S. Lai, Z.M. Spain, L. Greener, V. Turajlic, S. Larkin, J. Morganstein, D.L. (2021). Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH. J endocrinol invest, Vol.44 (1), pp. 195-203.  show abstract  full text

Ascierto, P.A. Dréno, B. Larkin, J. Ribas, A. Liszkay, G. Maio, M. Mandalà, M. Demidov, L. Stroyakovskiy, D. Thomas, L. de la Cruz-Merino, L. Atkinson, V. Dutriaux, C. Garbe, C. Hsu, J. Jones, S. Li, H. McKenna, E. Voulgari, A. McArthur, G.A. (2021). 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clin cancer res, Vol.27 (19), pp. 5225-5235.  show abstract  full text

Kostine, M. Finckh, A. Bingham, C.O. Visser, K. Leipe, J. Schulze-Koops, H. Choy, E.H. Benesova, K. Radstake, T.R. Cope, A.P. Lambotte, O. Gottenberg, J.-. Allenbach, Y. Visser, M. Rusthoven, C. Thomasen, L. Jamal, S. Marabelle, A. Larkin, J. Haanen, J.B. Calabrese, L.H. Mariette, X. Schaeverbeke, T. (2021). EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann rheum dis, Vol.80 (1), pp. 36-48.  show abstract  full text

Ho, B. Larkin, J. Heelan, K. (2021). Checkpoint Inhibitor-associated Cutaneous Small Vessel Vasculitis: A Review of the Literature. J immunother, Vol.44 (3), pp. 118-121.  show abstract

Aeppli, S. Schmaus, M. Eisen, T. Escudier, B. Grünwald, V. Larkin, J. McDermott, D. Oldenburg, J. Porta, C. Rini, B.I. Schmidinger, M. Sternberg, C.N. Rothermundt, C. Putora, P.M. (2021). First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. Esmo open, Vol.6 (1), p. 100030.  show abstract  full text

Saturno, G. Lopes, F. Niculescu-Duvaz, I. Niculescu-Duvaz, D. Zambon, A. Davies, L. Johnson, L. Preece, N. Lee, R. Viros, A. Holovanchuk, D. Pedersen, M. McLeary, R. Lorigan, P. Dhomen, N. Fisher, C. Banerji, U. Dean, E. Krebs, M.G. Gore, M. Larkin, J. Marais, R. Springer, C. (2021). The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers. Ann oncol, Vol.32 (2), pp. 269-278.  show abstract  full text

Foley, L. Larkin, J. Lombard-Vance, R. Murphy, A.W. Hynes, L. Galvin, E. Molloy, G.J. (2021). Prevalence and predictors of medication non-adherence among people living with multimorbidity: a systematic review and meta-analysis. Bmj open, Vol.11 (9), p. e044987.  show abstract

Edwards, C.L. Comito, F. Agraso Busto, S. Harland, C. Turajlic, S. Larkin, J. Heelan, K. Fearfield, L. (2021). Cutaneous toxicities in patients with melanoma receiving checkpoint inhibitor therapy: a retrospective review The experience of a single large specialist institution. Clin exp dermatol, Vol.46 (2), pp. 338-341.  show abstract

Gogas, H. Dréno, B. Larkin, J. Demidov, L. Stroyakovskiy, D. Eroglu, Z. Francesco Ferrucci, P. Pigozzo, J. Rutkowski, P. Mackiewicz, J. Rooney, I. Voulgari, A. Troutman, S. Pitcher, B. Guo, Y. Yan, Y. Castro, M. Mulla, S. Flaherty, K. Arance, A. (2021). Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. Ann oncol, Vol.32 (3), pp. 384-394.  show abstract

Ferguson, L. Ho, B. Weir, J. Francis, N. West, K. Rathbone, B. Larkin, J. Heelan, K. (2021). Extensive mucocutaneous, oesophageal and otic lichen planus secondary to nivolumab therapy. Skin health dis, Vol.1 (1), p. e8.  show abstract  full text

Litchfield, K. Reading, J.L. Puttick, C. Thakkar, K. Abbosh, C. Bentham, R. Watkins, T.B. Rosenthal, R. Biswas, D. Rowan, A. Lim, E. Al Bakir, M. Turati, V. Guerra-Assunção, J.A. Conde, L. Furness, A.J. Saini, S.K. Hadrup, S.R. Herrero, J. Lee, S.-. Van Loo, P. Enver, T. Larkin, J. Hellmann, M.D. Turajlic, S. Quezada, S.A. McGranahan, N. Swanton, C. (2021). Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell, Vol.184 (3), pp. 596-614.e14.  show abstract  full text

Tarhini, A.A. Toor, K. Chan, K. McDermott, D.F. Mohr, P. Larkin, J. Hodi, F.S. Lee, C.-. Rizzo, J.I. Johnson, H. Moshyk, A. Rao, S. Kotapati, S. Atkins, M.B. (2021). A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆. Esmo open, Vol.6 (2), p. 100050.  show abstract  full text

Larkin, J. Foley, L. Smith, S.M. Harrington, P. Clyne, B. (2021). The experience of financial burden for people with multimorbidity: A systematic review of qualitative research. Health expect, Vol.24 (2), pp. 282-295.  show abstract

Bottomley, A. Coens, C. Mierzynska, J. Blank, C.U. Mandalà, M. Long, G.V. Atkinson, V.G. Dalle, S. Haydon, A.M. Meshcheryakov, A. Khattak, A. Carlino, M.S. Sandhu, S. Puig, S. Ascierto, P.A. Larkin, J. Lorigan, P.C. Rutkowski, P. Schadendorf, D. Koornstra, R. Hernandez-Aya, L. Di Giacomo, A.M. van den Eertwegh, A.J. Grob, J.-. Gutzmer, R. Jamal, R. van Akkooi, A.C. Krepler, C. Ibrahim, N. Marreaud, S. Kicinski, M. Suciu, S. Robert, C. Eggermont, A.M. EORTC Melanoma Group, (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet oncol, Vol.22 (5), pp. 655-664.  show abstract

Eggermont, A.M. Blank, C.U. Mandalà, M. Long, G.V. Atkinson, V.G. Dalle, S. Haydon, A.M. Meshcheryakov, A. Khattak, A. Carlino, M.S. Sandhu, S. Larkin, J. Puig, S. Ascierto, P.A. Rutkowski, P. Schadendorf, D. Koornstra, R. Hernandez-Aya, L. Di Giacomo, A.M. van den Eertwegh, A.J. Grob, J.-. Gutzmer, R. Jamal, R. Lorigan, P.C. van Akkooi, A.C. Krepler, C. Ibrahim, N. Marreaud, S. Kicinski, M. Suciu, S. Robert, C. EORTC Melanoma Group, (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet oncol, Vol.22 (5), pp. 643-654.  show abstract

Kohoutova, D. Worku, D. Aziz, H. Teare, J. Weir, J. Larkin, J. (2021). Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options. Cells, Vol.10 (2).  show abstract  full text

Choueiri, T.K. Larkin, J. Pal, S. Motzer, R.J. Rini, B.I. Venugopal, B. Alekseev, B. Miyake, H. Gravis, G. Bilen, M.A. Hariharan, S. Chudnovsky, A. Ching, K.A. Mu, X.J. Mariani, M. Robbins, P.B. Huang, B. di Pietro, A. Albiges, L. (2021). Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. Esmo open, Vol.6 (3), p. 100101.  show abstract  full text

Alexander, J.L. Ibraheim, H. Sheth, B. Little, J. Khan, M.S. Richards, C. Hunter, N. Chauhan, D. Ratnakumaran, R. McHugh, K. Pinato, D.J. Nathan, P. Choy, J. Crusz, S.M. Furness, A. Turajlic, S. Pickering, L. Larkin, J. Teare, J.P. Papa, S. Speight, A. Sharma, A. Powell, N. (2021). Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. J immunother cancer, Vol.9 (7).  show abstract  full text

Percik, R. Larkin, J. Morganstein, D.L. (2021). Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis. Lancet oncol, Vol.22 (7), pp. 905-907.

Rzeniewicz, K. Larkin, J. Menzies, A.M. Turajlic, S. (2021). Immunotherapy use outside clinical trial populations: never say never?. Ann oncol, Vol.32 (7), pp. 866-880.  show abstract

Scherrer, E. Rau, R. Lorenzi, M. Shui, I. Townson, S. Larkin, J. (2021). Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced melanoma. Future oncol, Vol.17 (20), pp. 2683-2692.  show abstract  full text

Gudd, C.L. Au, L. Triantafyllou, E. Shum, B. Liu, T. Nathwani, R. Kumar, N. Mukherjee, S. Dhar, A. Woollard, K.J. Yone, Y. Pinato, D.J. Thursz, M.R. Goldin, R.D. Gore, M.E. Larkin, J. Khamri, W. Antoniades, C.G. Turajlic, S. Possamai, L.A. (2021). Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. J hepatol, Vol.75 (1), pp. 177-189.  show abstract  full text

Zhao, Y. Fu, X. Lopez, J.I. Rowan, A. Au, L. Fendler, A. Hazell, S. Xu, H. Horswell, S. Shepherd, S.T. Spain, L. Byrne, F. Stamp, G. O'Brien, T. Nicol, D. Augustine, M. Chandra, A. Rudman, S. Toncheva, A. Pickering, L. Sahai, E. Larkin, J. Bates, P.A. Swanton, C. Turajlic, S. TRACERx Renal Consortium, Litchfield, K. (2021). Selection of metastasis competent subclones in the tumour interior. Nat ecol evol, Vol.5 (7), pp. 1033-1045.  show abstract  full text

Au, L. Fendler, A. Shepherd, S.T. Rzeniewicz, K. Cerrone, M. Byrne, F. Carlyle, E. Edmonds, K. Del Rosario, L. Shon, J. Haynes, W.A. Ward, B. Shum, B. Gordon, W. Gerard, C.L. Xie, W. Joharatnam-Hogan, N. Young, K. Pickering, L. Furness, A.J. Larkin, J. Harvey, R. Kassiotis, G. Gandhi, S. Crick COVID-19 Consortium, Swanton, C. Fribbens, C. Wilkinson, K.A. Wilkinson, R.J. Lau, D.K. Banerjee, S. Starling, N. Chau, I. CAPTURE Consortium, Turajlic, S. (2021). Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. Nat med, Vol.27 (8), pp. 1362-1366.  show abstract  full text

Lidington, E. Darlington, A.S. Vlooswijk, C. Beardsworth, S. McCaffrey, S. Tang, S. Stallard, K. Younger, E. Edwards, P. Ali, A.I. Nandhabalan, M. Din, A. Starling, N. Larkin, J. Stanway, S. Nobbenhuis, M. Banerjee, S. Szucs, Z. Gonzalez, M. Sirohi, B. Husson, O. van der Graaf, W.T. (2021). Beyond Teenage and Young Adult Cancer Care: Care Experiences of Patients Aged 25-39 Years Old in the UK National Health Service. Clin oncol (r coll radiol), Vol.33 (8), pp. 494-506.  show abstract  full text

Au, L. Hatipoglu, E. Robert de Massy, M. Litchfield, K. Beattie, G. Rowan, A. Schnidrig, D. Thompson, R. Byrne, F. Horswell, S. Fotiadis, N. Hazell, S. Nicol, D. Shepherd, S.T. Fendler, A. Mason, R. Del Rosario, L. Edmonds, K. Lingard, K. Sarker, S. Mangwende, M. Carlyle, E. Attig, J. Joshi, K. Uddin, I. Becker, P.D. Sunderland, M.W. Akarca, A. Puccio, I. Yang, W.W. Lund, T. Dhillon, K. Vasquez, M.D. Ghorani, E. Xu, H. Spencer, C. López, J.I. Green, A. Mahadeva, U. Borg, E. Mitchison, M. Moore, D.A. Proctor, I. Falzon, M. Pickering, L. Furness, A.J. Reading, J.L. Salgado, R. Marafioti, T. Jamal-Hanjani, M. PEACE Consortium, Kassiotis, G. Chain, B. Larkin, J. Swanton, C. Quezada, S.A. Turajlic, S. TRACERx Renal Consortium, (2021). Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer cell, Vol.39 (11), pp. 1497-1518.e11.  show abstract  full text

Mandala, M. Larkin, J. Ascierto, P.A. Del Vecchio, M. Gogas, H. Cowey, C.L. Arance, A. Dalle, S. Schenker, M. Grob, J.-. Chiarion-Sileni, V. Marquez-Rodas, I. Butler, M.O. Di Giacomo, A.M. Lutzky, J. De La Cruz-Merino, L. Atkinson, V. Arenberger, P. Hill, A. Fecher, L. Millward, M. Khushalani, N.I. de Pril, V. Lobo, M. Weber, J. (2021). Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. J immunother cancer, Vol.9 (8).  show abstract  full text

Dearden, H. Au, L. Wang, D.Y. Zimmer, L. Eroglu, Z. Smith, J.L. Cuvietto, M. Khoo, C. Atkinson, V. Lo, S. Long, G.V. Sandhu, S. Ascierto, P.A. Carlino, M.S. Johnson, D.B. Larkin, J. Menzies, A.M. (2021). Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. Eur j cancer, Vol.153, pp. 168-178.  show abstract

Hepner, A. Atkinson, V.G. Larkin, J. Burrell, R.A. Carlino, M.S. Johnson, D.B. Zimmer, L. Tsai, K.K. Klein, O. Lo, S.N. Haydon, A. Bhave, P. Lyle, M. Pallan, L. Pires da Silva, I. Gerard, C. Michielin, O. Long, G.V. Menzies, A.M. (2021). Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy. Eur j cancer, Vol.153, pp. 213-222.  show abstract

Uthayakumar, A.K. Rudd, E. Noy, M. Weir, J. Larkin, J. Fearfield, L. (2021). Severe progressive scarring pembrolizumab-induced lichen planopilaris in a patient with metastatic melanoma. Australas j dermatol, Vol.62 (3), pp. 403-406.  show abstract

Oza, B. Frangou, E. Smith, B. Bryant, H. Kaplan, R. Choodari-Oskooei, B. Powles, T. Stewart, G.D. Albiges, L. Bex, A. Choueiri, T.K. Davis, I.D. Eisen, T. Fielding, A. Harrison, D. McWhirter, A. Mulhere, S. Nathan, P. Rini, B. Ritchie, A. Scovell, S. Shakeshaft, C. Stockler, M.R. Thorogood, N. Parmar, M.K. Larkin, J. Meade, A. (2021). RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Contemp clin trials, Vol.108, p. 106482.  show abstract  full text

Meade, A. Oza, B. Frangou, E. Smith, B. Bryant, H. Kaplan, R. Choodari-Oskooei, B. Powles, T. Stewart, G.D. Albiges, L. Bex, A. Choueiri, T.K. Davis, I.D. Eisen, T. Fielding, A. Harrison, D.J. McWhirter, A. Mulhere, S. Nathan, P. Rini, B. Ritchie, A. Scovell, S. Shakeshaft, C. Stockler, M.R. Thorogood, N. Larkin, J. Parmar, M.K. (2021). RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. Contemp clin trials, Vol.108, p. 106481.  show abstract  full text

Lidington, E. Vlooswijk, C. Stallard, K. Travis, E. Younger, E. Edwards, P. Nandhabalan, M. Hunter, N. Sarpal, N. Flett, D. Din, A. Starling, N. Larkin, J. Stanway, S. Nobbenhuis, M. Banerjee, S. Szucs, Z. Darlington, A.-. Gonzalez, M. Sirohi, B. van der Graaf, W.T. Husson, O. (2021). 'This is not part of my life plan': A qualitative study on the psychosocial experiences and practical challenges in young adults with cancer age 25 to 39 years at diagnosis. Eur j cancer care (engl), Vol.30 (5), p. e13458.  show abstract  full text

Hodi, F.S. Wolchok, J.D. Schadendorf, D. Larkin, J. Long, G.V. Qian, X. Saci, A. Young, T.C. Srinivasan, S. Chang, H. Tang, H. Wind-Rotolo, M. Rizzo, J.I. Jackson, D.G. Ascierto, P.A. (2021). TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. Cancer immunol res, Vol.9 (10), pp. 1202-1213.  show abstract  full text

Mendis, S. Ealing, J. Larkin, J. Turajlic, S. Carr, A. Bronstein, A. Kaski, D. (2021). Isolated imbalance due to bilateral vestibular failure following immune checkpoint inhibitor administration: two cases. Eur j cancer, Vol.156, pp. 187-189.

Moriarty, F. Larkin, J. Fahey, T. (2021). Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: An observational study. Health policy, Vol.125 (10), pp. 1297-1304.  show abstract

Larkin, J. Pericin, I. Collins, M. Smith, S.M. Byrne, D. Moriarty, F. (2021). GPs' perceptions of their relationship with the pharmaceutical industry: a qualitative study. Bjgp open, Vol.5 (5).  show abstract

Regan, M.M. Mantia, C.M. Werner, L. Tarhini, A.A. Larkin, J. Stephen Hodi, F. Wolchok, J. Postow, M.A. Stwalley, B. Moshyk, A. Ritchings, C. Re, S. van Dijck, W. McDermott, D.F. Atkins, M.B. (2021). Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. J immunother cancer, Vol.9 (11).  show abstract  full text

Carlino, M.S. Larkin, J. Long, G.V. (2021). Immune checkpoint inhibitors in melanoma. Lancet, Vol.398 (10304), pp. 1002-1014.  show abstract

Fendler, A. Shepherd, S.T. Au, L. Wilkinson, K.A. Wu, M. Byrne, F. Cerrone, M. Schmitt, A.M. Joharatnam-Hogan, N. Shum, B. Tippu, Z. Rzeniewicz, K. Boos, L.A. Harvey, R. Carlyle, E. Edmonds, K. Del Rosario, L. Sarker, S. Lingard, K. Mangwende, M. Holt, L. Ahmod, H. Korteweg, J. Foley, T. Bazin, J. Gordon, W. Barber, T. Emslie-Henry, A. Xie, W. Gerard, C.L. Deng, D. Wall, E.C. Agua-Doce, A. Namjou, S. Caidan, S. Gavrielides, M. MacRae, J.I. Kelly, G. Peat, K. Kelly, D. Murra, A. Kelly, K. O'Flaherty, M. Dowdie, L. Ash, N. Gronthoud, F. Shea, R.L. Gardner, G. Murray, D. Kinnaird, F. Cui, W. Pascual, J. Rodney, S. Mencel, J. Curtis, O. Stephenson, C. Robinson, A. Oza, B. Farag, S. Leslie, I. Rogiers, A. Iyengar, S. Ethell, M. Messiou, C. Cunningham, D. Chau, I. Starling, N. Turner, N. Welsh, L. van As, N. Jones, R.L. Droney, J. Banerjee, S. Tatham, K.C. O'Brien, M. Harrington, K. Bhide, S. Okines, A. Reid, A. Young, K. Furness, A.J. Pickering, L. Swanton, C. Crick COVID-19 Consortium, Gandhi, S. Gamblin, S. Bauer, D.L. Kassiotis, G. Kumar, S. Yousaf, N. Jhanji, S. Nicholson, E. Howell, M. Walker, S. Wilkinson, R.J. Larkin, J. Turajlic, S. CAPTURE Consortium, (2021). Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat cancer, Vol.2 (12), pp. 1305-1320.  show abstract  full text

Fendler, A. Au, L. Shepherd, S.T. Byrne, F. Cerrone, M. Boos, L.A. Rzeniewicz, K. Gordon, W. Shum, B. Gerard, C.L. Ward, B. Xie, W. Schmitt, A.M. Joharatnam-Hogan, N. Cornish, G.H. Pule, M. Mekkaoui, L. Ng, K.W. Carlyle, E. Edmonds, K. Rosario, L.D. Sarker, S. Lingard, K. Mangwende, M. Holt, L. Ahmod, H. Stone, R. Gomes, C. Flynn, H.R. Agua-Doce, A. Hobson, P. Caidan, S. Howell, M. Wu, M. Goldstone, R. Crawford, M. Cubitt, L. Patel, H. Gavrielides, M. Nye, E. Snijders, A.P. MacRae, J.I. Nicod, J. Gronthoud, F. Shea, R.L. Messiou, C. Cunningham, D. Chau, I. Starling, N. Turner, N. Welsh, L. van As, N. Jones, R.L. Droney, J. Banerjee, S. Tatham, K.C. Jhanji, S. O'Brien, M. Curtis, O. Harrington, K. Bhide, S. Bazin, J. Robinson, A. Stephenson, C. Slattery, T. Khan, Y. Tippu, Z. Leslie, I. Gennatas, S. Okines, A. Reid, A. Young, K. Furness, A.J. Pickering, L. Gandhi, S. Gamblin, S. Swanton, C. Crick COVID-19 Consortium, Nicholson, E. Kumar, S. Yousaf, N. Wilkinson, K.A. Swerdlow, A. Harvey, R. Kassiotis, G. Larkin, J. Wilkinson, R.J. Turajlic, S. CAPTURE consortium, (2021). Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nat cancer, Vol.2 (12), pp. 1321-1337.  show abstract  full text

Nogueira, E. Menon, A. Dede, A. Mitra, I. Brock, C. Larkin, J. Morganstein, D. (2021). Pituitary enlargement following ipilimumab without long term endocrine dysfunction. Curr probl cancer, Vol.45 (6), p. 100710.  show abstract

Meric-Bernstam, F. Larkin, J. Tabernero, J. Bonini, C. (2021). Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet, Vol.397 (10278), pp. 1010-1022.  show abstract

Eggermont, A.M. Meshcheryakov, A. Atkinson, V. Blank, C.U. Mandala, M. Long, G.V. Barrow, C. Di Giacomo, A.M. Fisher, R. Sandhu, S. Kudchadkar, R. Ortiz Romero, P.L. Svane, I.M. Larkin, J. Puig, S. Hersey, P. Quaglino, P. Queirolo, P. Stroyakovskiy, D. Bastholt, L. Mohr, P. Hernberg, M. Chiarion-Sileni, V. Strother, M. Hauschild, A. Yamazaki, N. van Akkooi, A.C. Lorigan, P. Krepler, C. Ibrahim, N. Marreaud, S. Kicinski, M. Suciu, S. Robert, C. (2021). Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. Eur j cancer, Vol.158, pp. 156-168.  show abstract  full text

McDermott, D.F. Lee, J.-. Bjarnason, G.A. Larkin, J.M. Gafanov, R.A. Kochenderfer, M.D. Jensen, N.V. Donskov, F. Malik, J. Poprach, A. Tykodi, S.S. Alonso-Gordoa, T. Cho, D.C. Geertsen, P.F. Climent Duran, M.A. DiSimone, C. Silverman, R.K. Perini, R.F. Schloss, C. Atkins, M.B. (2021). Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. J clin oncol, Vol.39 (9), pp. 1020-1028.  show abstract  full text

Sarnaik, A.A. Hamid, O. Khushalani, N.I. Lewis, K.D. Medina, T. Kluger, H.M. Thomas, S.S. Domingo-Musibay, E. Pavlick, A.C. Whitman, E.D. Martin-Algarra, S. Corrie, P. Curti, B.D. Oláh, J. Lutzky, J. Weber, J.S. Larkin, J.M. Shi, W. Takamura, T. Jagasia, M. Qin, H. Wu, X. Chartier, C. Graf Finckenstein, F. Fardis, M. Kirkwood, J.M. Chesney, J.A. (2021). Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J clin oncol, Vol.39 (24), pp. 2656-2666.  show abstract  full text

Collins, C. Finegan, P. O'Shea, M. Larkin, J. Pericin, I. Osborne, B. (2021). Promoting physical health among people with enduring mental illness: a qualitative study of healthcare providers' perspectives. Bmj open, Vol.11 (4), p. e044855.  show abstract

Eggermont, A.M. Kicinski, M. Blank, C.U. Mandala, M. Long, G.V. Atkinson, V. Dalle, S. Haydon, A. Khattak, A. Carlino, M.S. Sandhu, S. Larkin, J. Puig, S. Ascierto, P.A. Rutkowski, P. Schadendorf, D. Koornstra, R. Hernandez-Aya, L. Di Giacomo, A.M. van den Eertwegh, A.J. Grob, J.-. Gutzmer, R. Jamal, R. Lorigan, P.C. Krepler, C. Ibrahim, N. Marreaud, S. van Akkooi, A. Robert, C. Suciu, S. (2020). Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. Jama oncol, Vol.6 (4), pp. 519-527.  show abstract  full text

Peach, H. Board, R. Cook, M. Corrie, P. Ellis, S. Geh, J. King, P. Laitung, G. Larkin, J. Marsden, J. Middleton, M. Moncrieff, M. Nathan, P. Powell, B. Pritchard-Jones, R. Rodwell, S. Steven, N. Lorigan, P. (2020). Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement. J plast reconstr aesthet surg, Vol.73 (1), pp. 36-42.  show abstract

Eisen, T. Frangou, E. Oza, B. Ritchie, A.W. Smith, B. Kaplan, R. Davis, I.D. Stockler, M.R. Albiges, L. Escudier, B. Larkin, J. Bex, A. Joniau, S. Hancock, B. Hermann, G.G. Bellmunt, J. Hodgkinson, E. Stewart, G.D. Barber, J. Brown, J. McMenemin, R. Nathan, P. Pickering, L.M. Parmar, M.K. Meade, A. (2020). Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. J clin oncol, Vol.38 (34), pp. 4064-4075.  show abstract

O'Reilly, A. Hughes, P. Mann, J. Lai, Z. Teh, J.J. Mclean, E. Edmonds, K. Lingard, K. Chauhan, D. Lynch, J. Au, L. Ludlow, A. Pattison, N. Wiseman, T. Turajlic, S. Gore, M. Larkin, J. Husson, O. (2020). An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. Support care cancer, Vol.28 (2), pp. 561-570.  show abstract  full text

Ascierto, P.A. Ribas, A. Larkin, J. McArthur, G.A. Lewis, K.D. Hauschild, A. Flaherty, K.T. McKenna, E. Zhu, Q. Mun, Y. Dréno, B. (2020). Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials. J transl med, Vol.18 (1), p. 294.  show abstract  full text

Dummer, R. Brase, J.C. Garrett, J. Campbell, C.D. Gasal, E. Squires, M. Gusenleitner, D. Santinami, M. Atkinson, V. Mandalà, M. Chiarion-Sileni, V. Flaherty, K. Larkin, J. Robert, C. Kefford, R. Kirkwood, J.M. Hauschild, A. Schadendorf, D. Long, G.V. (2020). Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet oncol, Vol.21 (3), pp. 358-372.  show abstract

Piperno-Neumann, S. Larkin, J. Carvajal, R.D. Luke, J.J. Schwartz, G.K. Hodi, F.S. Sablin, M.-. Shoushtari, A.N. Szpakowski, S. Chowdhury, N.R. Brannon, A.R. Ramkumar, T. de Koning, L. Derti, A. Emery, C. Yerramilli-Rao, P. Kapiteijn, E. (2020). Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. Mol cancer ther, Vol.19 (4), pp. 1031-1039.  show abstract

Litchfield, K. Stanislaw, S. Spain, L. Gallegos, L.L. Rowan, A. Schnidrig, D. Rosenbaum, H. Harle, A. Au, L. Hill, S.M. Tippu, Z. Thomas, J. Thompson, L. Xu, H. Horswell, S. Barhoumi, A. Jones, C. Leith, K.F. Burgess, D.L. Watkins, T.B. Lim, E. Birkbak, N.J. Lamy, P. Nordentoft, I. Dyrskjøt, L. Pickering, L. Hazell, S. Jamal-Hanjani, M. PEACE Consortium, Larkin, J. Swanton, C. Alexander, N.R. Turajlic, S. (2020). Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell rep, Vol.31 (5), p. 107550.  show abstract  full text

Ugurel, S. Röhmel, J. Ascierto, P.A. Becker, J.C. Flaherty, K.T. Grob, J.J. Hauschild, A. Larkin, J. Livingstone, E. Long, G.V. Lorigan, P. McArthur, G.A. Ribas, A. Robert, C. Zimmer, L. Schadendorf, D. Garbe, C. (2020). Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. Eur j cancer, Vol.130, pp. 126-138.  show abstract

Leslie, I. Boos, L.A. Larkin, J. Pickering, L. (2020). Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy. Expert rev anticancer ther, Vol.20 (5), pp. 343-354.  show abstract

Haanen, J. Ernstoff, M.S. Wang, Y. Menzies, A.M. Puzanov, I. Grivas, P. Larkin, J. Peters, S. Thompson, J.A. Obeid, M. (2020). Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann oncol, Vol.31 (6), pp. 724-744.  show abstract

Haanen, J. Ernstoff, M. Wang, Y. Menzies, A. Puzanov, I. Grivas, P. Larkin, J. Peters, S. Thompson, J. Obeid, M. (2020). Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J immunother cancer, Vol.8 (1).  show abstract  full text

Boos, L.A. Leslie, I. Larkin, J. (2020). Metastatic melanoma: therapeutic agents in preclinical and early clinical development. Expert opin investig drugs, Vol.29 (7), pp. 739-753.  show abstract

Powell, N. Ibraheim, H. Raine, T. Speight, R.A. Papa, S. Brain, O. Green, M. Samaan, M.A. Spain, L. Yousaf, N. Hunter, N. Eldridge, L. Pavlidis, P. Irving, P. Hayee, B. Turajlic, S. Larkin, J. Lindsay, J.O. Gore, M. (2020). British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet gastroenterol hepatol, Vol.5 (7), pp. 679-697.  show abstract  full text

Aeppli, S. Eboulet, E.I. Eisen, T. Escudier, B. Fischer, S. Larkin, J. Gruenwald, V. McDermott, D. Oldenburg, J. Omlin, A. Porta, C. Rini, B. Schmidinger, M. Sternberg, C. Rothermundt, C. (2020). Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. Esmo open, Vol.5 (Suppl 3).  show abstract  full text

Favara, D.M. Spain, L. Au, L. Clark, J. Daniels, E. Diem, S. Chauhan, D. Turajlic, S. Powell, N. Larkin, J.M. Yousaf, N. (2020). Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. Esmo open, Vol.5 (4).  show abstract  full text

Choueiri, T.K. Motzer, R.J. Rini, B.I. Haanen, J. Campbell, M.T. Venugopal, B. Kollmannsberger, C. Gravis-Mescam, G. Uemura, M. Lee, J.L. Grimm, M.-. Gurney, H. Schmidinger, M. Larkin, J. Atkins, M.B. Pal, S.K. Wang, J. Mariani, M. Krishnaswami, S. Cislo, P. Chudnovsky, A. Fowst, C. Huang, B. di Pietro, A. Albiges, L. (2020). Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann oncol, Vol.31 (8), pp. 1030-1039.  show abstract  full text

Owen, C.N. Shoushtari, A.N. Chauhan, D. Palmieri, D.J. Lee, B. Rohaan, M.W. Mangana, J. Atkinson, V. Zaman, F. Young, A. Hoeller, C. Hersey, P. Dummer, R. Khattak, M.A. Millward, M. Patel, S.P. Haydon, A. Johnson, D.B. Lo, S. Blank, C.U. Sandhu, S. Carlino, M.S. Larkin, J.M. Menzies, A.M. Long, G.V. (2020). Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆. Ann oncol, Vol.31 (8), pp. 1075-1082.  show abstract

Sud, A. Torr, B. Jones, M.E. Broggio, J. Scott, S. Loveday, C. Garrett, A. Gronthoud, F. Nicol, D.L. Jhanji, S. Boyce, S.A. Williams, M. Riboli, E. Muller, D.C. Kipps, E. Larkin, J. Navani, N. Swanton, C. Lyratzopoulos, G. McFerran, E. Lawler, M. Houlston, R. Turnbull, C. (2020). Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet oncol, Vol.21 (8), pp. 1035-1044.  show abstract  full text

Sud, A. Jones, M.E. Broggio, J. Loveday, C. Torr, B. Garrett, A. Nicol, D.L. Jhanji, S. Boyce, S.A. Gronthoud, F. Ward, P. Handy, J.M. Yousaf, N. Larkin, J. Suh, Y.-. Scott, S. Pharoah, P.D. Swanton, C. Abbosh, C. Williams, M. Lyratzopoulos, G. Houlston, R. Turnbull, C. (2020). Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann oncol, Vol.31 (8), pp. 1065-1074.  show abstract  full text

Khushalani, N.I. Diab, A. Ascierto, P.A. Larkin, J. Sandhu, S. Sznol, M. Koon, H.B. Jarkowski, A. Zhou, M. Statkevich, P. Geese, W.J. Long, G.V. (2020). Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. Future oncol, Vol.16 (28), pp. 2165-2175.  show abstract

Comito, F. Leslie, I. Boos, L. Furness, A. Pickering, L. Turajlic, S. Larkin, J. (2020). Oligoprogression After Checkpoint Inhibition in Metastatic Melanoma Treated With Locoregional Therapy: A Single-center Retrospective Analysis. J immunother, Vol.43 (8), pp. 250-255.  show abstract

Schmidinger, M. Porta, C. Oudard, S. Denechere, G. Brault, Y. Serfass, L. Costa, N. Larkin, J. (2020). Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score. Clin genitourin cancer, Vol.18 (5), pp. e588-e597.  show abstract  full text

Motzer, R.J. Robbins, P.B. Powles, T. Albiges, L. Haanen, J.B. Larkin, J. Mu, X.J. Ching, K.A. Uemura, M. Pal, S.K. Alekseev, B. Gravis, G. Campbell, M.T. Penkov, K. Lee, J.L. Hariharan, S. Wang, X. Zhang, W. Wang, J. Chudnovsky, A. di Pietro, A. Donahue, A.C. Choueiri, T.K. (2020). Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat med, Vol.26 (11), pp. 1733-1741.  show abstract  full text

Ascierto, P.A. Del Vecchio, M. Mandalá, M. Gogas, H. Arance, A.M. Dalle, S. Cowey, C.L. Schenker, M. Grob, J.-. Chiarion-Sileni, V. Márquez-Rodas, I. Butler, M.O. Maio, M. Middleton, M.R. de la Cruz-Merino, L. Arenberger, P. Atkinson, V. Hill, A. Fecher, L.A. Millward, M. Khushalani, N.I. Queirolo, P. Lobo, M. de Pril, V. Loffredo, J. Larkin, J. Weber, J. (2020). Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet oncol, Vol.21 (11), pp. 1465-1477.  show abstract

de Boer, R.A. Hulot, J.-. Tocchetti, C.G. Aboumsallem, J.P. Ameri, P. Anker, S.D. Bauersachs, J. Bertero, E. Coats, A.J. Čelutkienė, J. Chioncel, O. Dodion, P. Eschenhagen, T. Farmakis, D. Bayes-Genis, A. Jäger, D. Jankowska, E.A. Kitsis, R.N. Konety, S.H. Larkin, J. Lehmann, L. Lenihan, D.J. Maack, C. Moslehi, J.J. Müller, O.J. Nowak-Sliwinska, P. Piepoli, M.F. Ponikowski, P. Pudil, R. Rainer, P.P. Ruschitzka, F. Sawyer, D. Seferovic, P.M. Suter, T. Thum, T. van der Meer, P. Van Laake, L.W. von Haehling, S. Heymans, S. Lyon, A.R. Backs, J. (2020). Common mechanistic pathways in cancer and heart failure A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur j heart fail, Vol.22 (12), pp. 2272-2289.  show abstract  full text

Hall, P.E. Shepherd, S.T. Brown, J. Larkin, J. Jones, R. Ralph, C. Hawkins, R. Chowdhury, S. Boleti, E. Bahl, A. Fife, K. Webb, A. Crabb, S.J. Geldart, T. Hill, R. Dunlop, J. McLaren, D. Ackerman, C. Wimalasingham, A. Beltran, L. Nathan, P. Powles, T. (2020). Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. Eur urol focus, Vol.6 (5), pp. 999-1005.  show abstract

Maio, M. Hamid, O. Larkin, J. Covre, A. Altomonte, M. Calabrò, L. Vardhana, S.A. Robert, C. Ibrahim, R. Anichini, A. Wolchok, J.D. Giacomo, A.M. (2020). Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. Clin cancer res, Vol.26 (16), pp. 4201-4205.  show abstract  full text

Motzer, R.J. Escudier, B. George, S. Hammers, H.J. Srinivas, S. Tykodi, S.S. Sosman, J.A. Plimack, E.R. Procopio, G. McDermott, D.F. Castellano, D. Choueiri, T.K. Donskov, F. Gurney, H. Oudard, S. Richardet, M. Peltola, K. Alva, A.S. Carducci, M. Wagstaff, J. Chevreau, C. Fukasawa, S. Tomita, Y. Gauler, T.C. Kollmannsberger, C.K. Schutz, F.A. Larkin, J. Cella, D. McHenry, M.B. Saggi, S.S. Tannir, N.M. (2020). Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer, Vol.126 (18), pp. 4156-4167.  show abstract

Dummer, R. Hauschild, A. Santinami, M. Atkinson, V. Mandalà, M. Kirkwood, J.M. Chiarion Sileni, V. Larkin, J. Nyakas, M. Dutriaux, C. Haydon, A. Robert, C. Mortier, L. Schachter, J. Lesimple, T. Plummer, R. Dasgupta, K. Gasal, E. Tan, M. Long, G.V. Schadendorf, D. (2020). Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N engl j med, Vol.383 (12), pp. 1139-1148.  show abstract

Yeom, M. Caraballo, L. Tsang, G. Larkin, J. Comrie, J. (2020). Reimagining impact: Storying youth research, arts, and activism. Review of education, pedagogy, and cultural studies, Vol.42 (5), pp. 482-503.

Eggermont, A.M. Blank, C.U. Mandala, M. Long, G.V. Atkinson, V.G. Dalle, S. Haydon, A.M. Meshcheryakov, A. Khattak, A. Carlino, M.S. Sandhu, S. Larkin, J. Puig, S. Ascierto, P.A. Rutkowski, P. Schadendorf, D. Koornstra, R. Hernandez-Aya, L. Di Giacomo, A.M. van den Eertwegh, A.J. Grob, J.-. Gutzmer, R. Jamal, R. Lorigan, P.C. van Akkooi, A.C. Krepler, C. Ibrahim, N. Marreaud, S. Kicinski, M. Suciu, S. Robert, C. (2020). Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. J clin oncol, Vol.38 (33), pp. 3925-3936.  show abstract  full text

Litchfield, K. Reading, J.L. Lim, E.L. Xu, H. Liu, P. Al-Bakir, M. Wong, Y.N. Rowan, A. Funt, S.A. Merghoub, T. Perkins, D. Lauss, M. Svane, I.M. Jönsson, G. Herrero, J. Larkin, J. Quezada, S.A. Hellmann, M.D. Turajlic, S. Swanton, C. (2020). Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. Nat commun, Vol.11 (1), p. 3800.  show abstract  full text

Johansson, M. Carreras-Torres, R. Scelo, G. Purdue, M.P. Mariosa, D. Muller, D.C. Timpson, N.J. Haycock, P.C. Brown, K.M. Wang, Z. Ye, Y. Hofmann, J.N. Foll, M. Gaborieau, V. Machiela, M.J. Colli, L.M. Li, P. Garnier, J.-. Blanche, H. Boland, A. Burdette, L. Prokhortchouk, E. Skryabin, K.G. Yeager, M. Radojevic-Skodric, S. Ognjanovic, S. Foretova, L. Holcatova, I. Janout, V. Mates, D. Mukeriya, A. Rascu, S. Zaridze, D. Bencko, V. Cybulski, C. Fabianova, E. Jinga, V. Lissowska, J. Lubinski, J. Navratilova, M. Rudnai, P. Benhamou, S. Cancel-Tassin, G. Cussenot, O. Weiderpass, E. Ljungberg, B. Tumkur Sitaram, R. Häggström, C. Bruinsma, F. Jordan, S.J. Severi, G. Winship, I. Hveem, K. Vatten, L.J. Fletcher, T. Larsson, S.C. Wolk, A. Banks, R.E. Selby, P.J. Easton, D.F. Andreotti, G. Beane Freeman, L.E. Koutros, S. Männistö, S. Weinstein, S. Clark, P.E. Edwards, T.L. Lipworth, L. Gapstur, S.M. Stevens, V.L. Carol, H. Freedman, M.L. Pomerantz, M.M. Cho, E. Wilson, K.M. Gaziano, J.M. Sesso, H.D. Freedman, N.D. Parker, A.S. Eckel-Passow, J.E. Huang, W.-. Kahnoski, R.J. Lane, B.R. Noyes, S.L. Petillo, D. Teh, B.T. Peters, U. White, E. Anderson, G.L. Johnson, L. Luo, J. Buring, J. Lee, I.-. Chow, W.-. Moore, L.E. Eisen, T. Henrion, M. Larkin, J. Barman, P. Leibovich, B.C. Choueiri, T.K. Lathrop, G.M. Deleuze, J.-. Gunter, M. McKay, J.D. Wu, X. Houlston, R.S. Chanock, S.J. Relton, C. Richards, J.B. Martin, R.M. Davey Smith, G. Brennan, P. (2019). The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study. Plos med, Vol.16 (1), p. e1002724.  show abstract  full text

Larkin, J. Brown, M.P. Arance, A.M. Hauschild, A. Queirolo, P. Vecchio, M.D. Ascierto, P.A. Krajsová, I. Schachter, J. Neyns, B. Garbe, C. Sileni, V.C. Mandalà, M. Gogas, H. Espinosa, E. Hospers, G. Lorigan, P. Nyakas, M. Guminski, A. Liszkay, G. Rutkowski, P. Miller, W. Donica, M. Makrutzki, M. Blank, C. (2019). An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. Eur j cancer, Vol.107, pp. 175-185.  show abstract

Yan, Y. Wongchenko, M.J. Robert, C. Larkin, J. Ascierto, P.A. Dréno, B. Maio, M. Garbe, C. Chapman, P.B. Sosman, J.A. Shi, Z. Koeppen, H. Hsu, J.J. Chang, I. Caro, I. Rooney, I. McArthur, G.A. Ribas, A. (2019). Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma. Clin cancer res, Vol.25 (11), pp. 3239-3246.  show abstract

Robert, C. Flaherty, K. Nathan, P. Hersey, P. Garbe, C. Milhem, M. Demidov, L. Mohr, P. Hassel, J.C. Rutkowski, P. Dummer, R. Utikal, J. Kiecker, F. Larkin, J. D'Amelio, A. Mookerjee, B. Schadendorf, D. (2019). Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma. Eur j cancer, Vol.109, pp. 61-69.  show abstract

Hayes, A.J. Moskovic, E. O'Meara, K. Smith, H.G. Pope, R.J. Larkin, J. Thomas, J.M. (2019). Prospective cohort study of ultrasound surveillance of regional lymph nodes in patients with intermediate-risk cutaneous melanoma. Br j surg, Vol.106 (6), pp. 729-734.  show abstract  full text

Schadendorf, D. Hauschild, A. Santinami, M. Atkinson, V. Mandalà, M. Chiarion-Sileni, V. Larkin, J. Nyakas, M. Dutriaux, C. Haydon, A. Robert, C. Mortier, L. Lesimple, T. Plummer, R. Schachter, J. Dasgupta, K. Manson, S. Koruth, R. Mookerjee, B. Kefford, R. Dummer, R. Kirkwood, J.M. Long, G.V. (2019). Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet oncol, Vol.20 (5), pp. 701-710.  show abstract

Mason, R. Au, L. Ingles Garces, A. Larkin, J. (2019). Current and emerging systemic therapies for cutaneous metastatic melanoma. Expert opin pharmacother, Vol.20 (9), pp. 1135-1152.  show abstract

Lewis, K. Hauschild, A. Larkin, J. Ribas, A. Flaherty, K.T. McArthur, G.A. Dréno, B. McKenna, E. Zhu, Q. Mun, Y. Ascierto, P.A. (2019). Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib. Eur j cancer, Vol.116, pp. 45-55.  show abstract

Kreft, S. Gesierich, A. Eigentler, T. Franklin, C. Valpione, S. Ugurel, S. Utikal, J. Haferkamp, S. Blank, C. Larkin, J. Garbe, C. Schadendorf, D. Lorigan, P. Schilling, B. (2019). Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. Eur j cancer, Vol.116, pp. 207-215.  show abstract

Eggermont, A.M. Blank, C.U. Mandala, M. Long, G.V. Atkinson, V.G. Dalle, S. Haydon, A. Lichinitser, M. Khattak, A. Carlino, M.S. Sandhu, S. Larkin, J. Puig, S. Ascierto, P.A. Rutkowski, P. Schadendorf, D. Koornstra, R. Hernandez-Aya, L. Di Giacomo, A.M. van den Eertwegh, A.J. Grob, J.-. Gutzmer, R. Jamal, R. Lorigan, P.C. Lupinacci, R. Krepler, C. Ibrahim, N. Kicinski, M. Marreaud, S. van Akkooi, A.C. Suciu, S. Robert, C. (2019). Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. Eur j cancer, Vol.116, pp. 148-157.  show abstract

Long, G.V. Dummer, R. Hamid, O. Gajewski, T.F. Caglevic, C. Dalle, S. Arance, A. Carlino, M.S. Grob, J.-. Kim, T.M. Demidov, L. Robert, C. Larkin, J. Anderson, J.R. Maleski, J. Jones, M. Diede, S.J. Mitchell, T.C. (2019). Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet oncol, Vol.20 (8), pp. 1083-1097.  show abstract

Ingles Garces, A.H. Au, L. Mason, R. Thomas, J. Larkin, J. (2019). Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer. Expert opin investig drugs, Vol.28 (8), pp. 695-708.  show abstract

Michaelson, M.D. Gupta, S. Agarwal, N. Szmulewitz, R. Powles, T. Pili, R. Bruce, J.Y. Vaishampayan, U. Larkin, J. Rosbrook, B. Wang, E. Murphy, D. Wang, P. Lechuga, M.J. Valota, O. Shepard, D.R. (2019). A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. Oncologist, Vol.24 (9), pp. 1151-e817.  show abstract

Robert, C. Ribas, A. Schachter, J. Arance, A. Grob, J.-. Mortier, L. Daud, A. Carlino, M.S. McNeil, C.M. Lotem, M. Larkin, J.M. Lorigan, P. Neyns, B. Blank, C.U. Petrella, T.M. Hamid, O. Su, S.-. Krepler, C. Ibrahim, N. Long, G.V. (2019). Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet oncol, Vol.20 (9), pp. 1239-1251.  show abstract

Regan, M.M. Werner, L. Rao, S. Gupte-Singh, K. Hodi, F.S. Kirkwood, J.M. Kluger, H.M. Larkin, J. Postow, M.A. Ritchings, C. Sznol, M. Tarhini, A.A. Wolchok, J.D. Atkins, M.B. McDermott, D.F. (2019). Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. J clin oncol, Vol.37 (35), pp. 3350-3358.  show abstract  full text

Lewis, K.D. Larkin, J. Ribas, A. Flaherty, K.T. McArthur, G.A. Ascierto, P.A. Dréno, B. Yan, Y. Wongchenko, M. McKenna, E. Zhu, Q. Mun, Y. Hauschild, A. (2019). Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. Br j cancer, Vol.121 (7), pp. 522-528.  show abstract  full text

Long, G.V. Flaherty, K.T. Stroyakovskiy, D. Gogas, H. Levchenko, E. de Braud, F. Larkin, J. Garbe, C. Jouary, T. Hauschild, A. Chiarion-Sileni, V. Lebbe, C. Mandala, M. Millward, M. Arance, A. Bondarenko, I. Haanen, J.B. Hansson, J. Utikal, J. Ferraresi, V. Mohr, P. Probachai, V. Schadendorf, D. Nathan, P. Robert, C. Ribas, A. Davies, M.A. Lane, S.R. Legos, J.J. Mookerjee, B. Grob, J.-. (2019). Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (vol 28, pg 1631, 2017). Annals of oncology, Vol.30 (11), pp. 1848-1.

Masiero, M. Li, D. Whiteman, P. Bentley, C. Greig, J. Hassanali, T. Watts, S. Stribbling, S. Yates, J. Bealing, E. Li, J.-. Chillakuri, C. Sheppard, D. Serres, S. Sarmiento-Soto, M. Larkin, J. Sibson, N.R. Handford, P.A. Harris, A.L. Banham, A.H. (2019). Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer Therapy. Mol cancer ther, Vol.18 (11), pp. 2030-2042.  show abstract  full text

Buckley, H.L. Collinson, F.J. Ainsworth, G. Poad, H. Flanagan, L. Katona, E. Howard, H.C. Murden, G. Banks, R.E. Brown, J. Velikova, G. Waddell, T. Fife, K. Nathan, P.D. Larkin, J. Powles, T. Brown, S.R. Vasudev, N.S. (2019). PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. Bmc cancer, Vol.19 (1), p. 1102.  show abstract  full text

Larkin, J. Chiarion-Sileni, V. Gonzalez, R. Grob, J.-. Rutkowski, P. Lao, C.D. Cowey, C.L. Schadendorf, D. Wagstaff, J. Dummer, R. Ferrucci, P.F. Smylie, M. Hogg, D. Hill, A. Márquez-Rodas, I. Haanen, J. Guidoboni, M. Maio, M. Schöffski, P. Carlino, M.S. Lebbé, C. McArthur, G. Ascierto, P.A. Daniels, G.A. Long, G.V. Bastholt, L. Rizzo, J.I. Balogh, A. Moshyk, A. Hodi, F.S. Wolchok, J.D. (2019). Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N engl j med, Vol.381 (16), pp. 1535-1546.  show abstract

Motzer, R.J. Penkov, K. Haanen, J. Rini, B. Albiges, L. Campbell, M.T. Venugopal, B. Kollmannsberger, C. Negrier, S. Uemura, M. Lee, J.L. Vasiliev, A. Miller, W.H. Gurney, H. Schmidinger, M. Larkin, J. Atkins, M.B. Bedke, J. Alekseev, B. Wang, J. Mariani, M. Robbins, P.B. Chudnovsky, A. Fowst, C. Hariharan, S. Huang, B. di Pietro, A. Choueiri, T.K. (2019). Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N engl j med, Vol.380 (12), pp. 1103-1115.  show abstract  full text

Spain, L. Tippu, Z. Larkin, J.M. Carr, A. Turajlic, S. (2019). How we treat neurological toxicity from immune checkpoint inhibitors. Esmo open, Vol.4 (Suppl 4), p. e000540.  show abstract  full text

Larkin, J. Minor, D. D'Angelo, S. Neyns, B. Smylie, M. Miller, W.H. Gutzmer, R. Linette, G. Chmielowski, B. Lao, C.D. Lorigan, P. Grossmann, K. Hassel, J.C. Sznol, M. Daud, A. Sosman, J. Khushalani, N. Schadendorf, D. Hoeller, C. Walker, D. Kong, G. Horak, C. Weber, J. (2018). Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J clin oncol, Vol.36 (4), pp. 383-390.  show abstract  full text

Hauschild, A. Larkin, J. Ribas, A. Dréno, B. Flaherty, K.T. Ascierto, P.A. Lewis, K.D. McKenna, E. Zhu, Q. Mun, Y. McArthur, G.A. (2018). Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. Jama oncol, Vol.4 (10), pp. 1382-1388.  show abstract

Haanen, J.B. Carbonnel, F. Robert, C. Kerr, K.M. Peters, S. Larkin, J. Jordan, K. ESMO Guidelines Committee, (2018). Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann oncol, Vol.29 (Suppl 4), pp. iv264-iv266.

Grob, J.J. Schadendorf, D. Lorigan, P. Ascierto, P. Larkin, J. Nathan, P. Robert, C. Hauschild, A. Weber, J. Daud, A. Hamid, O. Dummer, R. Hansson, J. Hoeller, C. Schachter, J. Van Akkooi, A.C. Garbe, C. (2018). Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. Eur j cancer, Vol.91, pp. 168-170.  full text

Valpione, S. Carlino, M.S. Mangana, J. Mooradian, M.J. McArthur, G. Schadendorf, D. Hauschild, A. Menzies, A.M. Arance, A. Ascierto, P.A. Di Giacomo, A. de Rosa, F. Larkin, J. Park, J.J. Goldinger, S.M. Sullivan, R.J. Xu, W. Livingstone, E. Weichenthal, M. Rai, R. Gaba, L. Long, G.V. Lorigan, P. (2018). Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. Eur j cancer, Vol.91, pp. 116-124.  show abstract  full text

Choueiri, T.K. Larkin, J. Oya, M. Thistlethwaite, F. Martignoni, M. Nathan, P. Powles, T. McDermott, D. Robbins, P.B. Chism, D.D. Cho, D. Atkins, M.B. Gordon, M.S. Gupta, S. Uemura, H. Tomita, Y. Compagnoni, A. Fowst, C. di Pietro, A. Rini, B.I. (2018). Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet oncol, Vol.19 (4), pp. 451-460.  show abstract

Wongchenko, M.J. Ribas, A. Dréno, B. Ascierto, P.A. McArthur, G.A. Gallo, J.D. Rooney, I.A. Hsu, J. Koeppen, H. Yan, Y. Larkin, J. (2018). Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. Pigment cell melanoma res, Vol.31 (4), pp. 516-522.  show abstract  full text

Higham, C.E. Olsson-Brown, A. Carroll, P. Cooksley, T. Larkin, J. Lorigan, P. Morganstein, D. Trainer, P.J. Society for Endocrinology Clinical Committee, (2018). SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr connect, Vol.7 (7), pp. G1-G7.  show abstract  full text

Arce Vargas, F. Furness, A.J. Litchfield, K. Joshi, K. Rosenthal, R. Ghorani, E. Solomon, I. Lesko, M.H. Ruef, N. Roddie, C. Henry, J.Y. Spain, L. Ben Aissa, A. Georgiou, A. Wong, Y.N. Smith, M. Strauss, D. Hayes, A. Nicol, D. O'Brien, T. Mårtensson, L. Ljungars, A. Teige, I. Frendéus, B. TRACERx Melanoma, TRACERx Renal, TRACERx Lung consortia, Pule, M. Marafioti, T. Gore, M. Larkin, J. Turajlic, S. Swanton, C. Peggs, K.S. Quezada, S.A. (2018). Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer cell, Vol.33 (4), pp. 649-663.e4.  show abstract  full text

Lyon, A.R. Yousaf, N. Battisti, N.M. Moslehi, J. Larkin, J. (2018). Immune checkpoint inhibitors and cardiovascular toxicity. Lancet oncol, Vol.19 (9), pp. e447-e458.  show abstract

Eggermont, A.M. Blank, C.U. Mandala, M. Long, G.V. Atkinson, V. Dalle, S. Haydon, A. Lichinitser, M. Khattak, A. Carlino, M.S. Sandhu, S. Larkin, J. Puig, S. Ascierto, P.A. Rutkowski, P. Schadendorf, D. Koornstra, R. Hernandez-Aya, L. Maio, M. van den Eertwegh, A.J. Grob, J.-. Gutzmer, R. Jamal, R. Lorigan, P. Ibrahim, N. Marreaud, S. van Akkooi, A.C. Suciu, S. Robert, C. (2018). Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N engl j med, Vol.378 (19), pp. 1789-1801.  show abstract  full text

Hauschild, A. Dummer, R. Schadendorf, D. Santinami, M. Atkinson, V. Mandalà, M. Chiarion-Sileni, V. Larkin, J. Nyakas, M. Dutriaux, C. Haydon, A. Robert, C. Mortier, L. Schachter, J. Lesimple, T. Plummer, R. Dasgupta, K. Haas, T. Shilkrut, M. Gasal, E. Kefford, R. Kirkwood, J.M. Long, G.V. (2018). Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J clin oncol, Vol.36 (35), pp. 3441-3449.  show abstract  full text

Sun, M. Marconi, L. Eisen, T. Escudier, B. Giles, R.H. Haas, N.B. Harshman, L.C. Quinn, D.I. Larkin, J. Pal, S.K. Powles, T. Ryan, C.W. Sternberg, C.N. Uzzo, R. Choueiri, T.K. Bex, A. (2018). Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. Eur urol, Vol.74 (5), pp. 611-620.  show abstract  full text

Smith, M.J. Smith, H.G. Joshi, K. Gore, M. Strauss, D.C. Hayes, A.J. Larkin, J. (2018). The impact of effective systemic therapies on surgery for stage IV melanoma. Eur j cancer, Vol.103, pp. 24-31.  show abstract

Hodi, F.S. Chiarion-Sileni, V. Gonzalez, R. Grob, J.-. Rutkowski, P. Cowey, C.L. Lao, C.D. Schadendorf, D. Wagstaff, J. Dummer, R. Ferrucci, P.F. Smylie, M. Hill, A. Hogg, D. Marquez-Rodas, I. Jiang, J. Rizzo, J. Larkin, J. Wolchok, J.D. (2018). Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet oncol, Vol.19 (11), pp. 1480-1492.  show abstract

Wongchenko, M.J. Ribas, A. Ascierto, P.A. Dréno, B. Maria di Giacomo, A. Garbe, C. Chang, I. Hsu, J. Rooney, I. Lu, W. Koeppen, H. Larkin, J. Yan, Y. McArthur, G.A. (2018). Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study. Jco precis oncol, Vol.2, pp. 1-18.  show abstract

Lu, W. Burton, L. Larkin, J. Chapman, P.B. Ascierto, P.A. Ribas, A. Robert, C. Sosman, J.A. McArthur, G.A. Chang, I. Caro, I. Penuel, E. Yan, Y. Wongchenko, M.J. (2018). Elevated Levels of BRAFV600 Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma. Jco precis oncol, Vol.2, pp. 1-17.  show abstract

Grob, J.J. Garbe, C. Ascierto, P. Larkin, J. Dummer, R. Schadendorf, D. (2018). Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?. Lancet oncol, Vol.19 (12), pp. e720-e725.  show abstract

Turajlic, S. Xu, H. Litchfield, K. Rowan, A. Horswell, S. Chambers, T. O'Brien, T. Lopez, J.I. Watkins, T.B. Nicol, D. Stares, M. Challacombe, B. Hazell, S. Chandra, A. Mitchell, T.J. Au, L. Eichler-Jonsson, C. Jabbar, F. Soultati, A. Chowdhury, S. Rudman, S. Lynch, J. Fernando, A. Stamp, G. Nye, E. Stewart, A. Xing, W. Smith, J.C. Escudero, M. Huffman, A. Matthews, N. Elgar, G. Phillimore, B. Costa, M. Begum, S. Ward, S. Salm, M. Boeing, S. Fisher, R. Spain, L. Navas, C. Grönroos, E. Hobor, S. Sharma, S. Aurangzeb, I. Lall, S. Polson, A. Varia, M. Horsfield, C. Fotiadis, N. Pickering, L. Schwarz, R.F. Silva, B. Herrero, J. Luscombe, N.M. Jamal-Hanjani, M. Rosenthal, R. Birkbak, N.J. Wilson, G.A. Pipek, O. Ribli, D. Krzystanek, M. Csabai, I. Szallasi, Z. Gore, M. McGranahan, N. Van Loo, P. Campbell, P. Larkin, J. Swanton, C. TRACERx Renal Consortium, (2018). Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell, Vol.173 (3), pp. 595-610.e11.  show abstract  full text

Turajlic, S. Xu, H. Litchfield, K. Rowan, A. Chambers, T. Lopez, J.I. Nicol, D. O'Brien, T. Larkin, J. Horswell, S. Stares, M. Au, L. Jamal-Hanjani, M. Challacombe, B. Chandra, A. Hazell, S. Eichler-Jonsson, C. Soultati, A. Chowdhury, S. Rudman, S. Lynch, J. Fernando, A. Stamp, G. Nye, E. Jabbar, F. Spain, L. Lall, S. Guarch, R. Falzon, M. Proctor, I. Pickering, L. Gore, M. Watkins, T.B. Ward, S. Stewart, A. DiNatale, R. Becerra, M.F. Reznik, E. Hsieh, J.J. Richmond, T.A. Mayhew, G.F. Hill, S.M. McNally, C.D. Jones, C. Rosenbaum, H. Stanislaw, S. Burgess, D.L. Alexander, N.R. Swanton, C. PEACE, TRACERx Renal Consortium, (2018). Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell, Vol.173 (3), pp. 581-594.e12.  show abstract  full text

Mitchell, T.J. Turajlic, S. Rowan, A. Nicol, D. Farmery, J.H. O'Brien, T. Martincorena, I. Tarpey, P. Angelopoulos, N. Yates, L.R. Butler, A.P. Raine, K. Stewart, G.D. Challacombe, B. Fernando, A. Lopez, J.I. Hazell, S. Chandra, A. Chowdhury, S. Rudman, S. Soultati, A. Stamp, G. Fotiadis, N. Pickering, L. Au, L. Spain, L. Lynch, J. Stares, M. Teague, J. Maura, F. Wedge, D.C. Horswell, S. Chambers, T. Litchfield, K. Xu, H. Stewart, A. Elaidi, R. Oudard, S. McGranahan, N. Csabai, I. Gore, M. Futreal, P.A. Larkin, J. Lynch, A.G. Szallasi, Z. Swanton, C. Campbell, P.J. TRACERx Renal Consortium, (2018). Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. Cell, Vol.173 (3), pp. 611-623.e17.  show abstract  full text

Proskorovsky, I. Benedict, A. Negrier, S. Bargo, D. Sandin, R. Ramaswamy, K. Desai, J. Cappelleri, J.C. Larkin, J. (2018). Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses. Bmc cancer, Vol.18 (1), p. 1271.  show abstract  full text

Dréno, B. Ascierto, P.A. Atkinson, V. Liszkay, G. Maio, M. Mandalà, M. Demidov, L. Stroyakovskiy, D. Thomas, L. de la Cruz-Merino, L. Dutriaux, C. Garbe, C. Bartley, K. Karagiannis, T. Chang, I. Rooney, I. Koralek, D.O. Larkin, J. McArthur, G.A. Ribas, A. (2018). Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma. Br j cancer, Vol.118 (6), pp. 777-784.  show abstract  full text

Lim, K.H. Spain, L. Barker, C. Georgiou, A. Walls, G. Gore, M. Turajlic, S. Board, R. Larkin, J.M. Lorigan, P. (2018). Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. Esmo open, Vol.3 (2), p. e000317.  show abstract  full text

Flynn, M. Pickering, L. Larkin, J. Turajlic, S. (2018). Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. Ther adv med oncol, Vol.10, p. 1758835918777427.  show abstract  full text

Winkler, T. Larkin, J. Rissanen, K. (2018). People. Chemistry & industry, Vol.82 (3), pp. 14-1.

Spain, L. Walls, G. Messiou, C. Turajlic, S. Gore, M. Larkin, J. (2017). Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. Cancer immunol immunother, Vol.66 (1), pp. 113-117.  show abstract  full text

Wongchenko, M.J. McArthur, G.A. Dréno, B. Larkin, J. Ascierto, P.A. Sosman, J. Andries, L. Kockx, M. Hurst, S.D. Caro, I. Rooney, I. Hegde, P.S. Molinero, L. Yue, H. Chang, I. Amler, L. Yan, Y. Ribas, A. (2017). Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clin cancer res, Vol.23 (17), pp. 5238-5245.  show abstract  full text

Long, G.V. Weber, J.S. Larkin, J. Atkinson, V. Grob, J.-. Schadendorf, D. Dummer, R. Robert, C. Márquez-Rodas, I. McNeil, C. Schmidt, H. Briscoe, K. Baurain, J.-. Hodi, F.S. Wolchok, J.D. (2017). Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. Jama oncol, Vol.3 (11), pp. 1511-1519.  show abstract  full text

Schadendorf, D. Wolchok, J.D. Hodi, F.S. Chiarion-Sileni, V. Gonzalez, R. Rutkowski, P. Grob, J.-. Cowey, C.L. Lao, C.D. Chesney, J. Robert, C. Grossmann, K. McDermott, D. Walker, D. Bhore, R. Larkin, J. Postow, M.A. (2017). Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J clin oncol, Vol.35 (34), pp. 3807-3814.  show abstract  full text

Chapman, P.B. Robert, C. Larkin, J. Haanen, J.B. Ribas, A. Hogg, D. Hamid, O. Ascierto, P.A. Testori, A. Lorigan, P.C. Dummer, R. Sosman, J.A. Flaherty, K.T. Chang, I. Coleman, S. Caro, I. Hauschild, A. McArthur, G.A. (2017). Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann oncol, Vol.28 (10), pp. 2581-2587.  show abstract  full text

Helgadottir, H. Kis, L. Ljungman, P. Larkin, J. Kefford, R. Ascierto, P.A. Hansson, J. Masucci, G. (2017). Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. Ann oncol, Vol.28 (7), pp. 1672-1673.  full text

Long, G.V. Flaherty, K.T. Stroyakovskiy, D. Gogas, H. Levchenko, E. de Braud, F. Larkin, J. Garbe, C. Jouary, T. Hauschild, A. Chiarion-Sileni, V. Lebbe, C. Mandalà, M. Millward, M. Arance, A. Bondarenko, I. Haanen, J.B. Hansson, J. Utikal, J. Ferraresi, V. Mohr, P. Probachai, V. Schadendorf, D. Nathan, P. Robert, C. Ribas, A. Davies, M.A. Lane, S.R. Legos, J.J. Mookerjee, B. Grob, J.-. (2017). Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann oncol, Vol.28 (7), pp. 1631-1639.  show abstract  full text

Spain, L. Walls, G. Julve, M. O'Meara, K. Schmid, T. Kalaitzaki, E. Turajlic, S. Gore, M. Rees, J. Larkin, J. (2017). Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann oncol, Vol.28 (2), pp. 377-385.  show abstract  full text

Dréno, B. Ribas, A. Larkin, J. Ascierto, P.A. Hauschild, A. Thomas, L. Grob, J.-. Koralek, D.O. Rooney, I. Hsu, J.J. McKenna, E.F. McArthur, G.A. (2017). Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann oncol, Vol.28 (5), pp. 1137-1144.  show abstract  full text

Bridgeman, V.L. Vermeulen, P.B. Foo, S. Bilecz, A. Daley, F. Kostaras, E. Nathan, M.R. Wan, E. Frentzas, S. Schweiger, T. Hegedus, B. Hoetzenecker, K. Renyi-Vamos, F. Kuczynski, E.A. Vasudev, N.S. Larkin, J. Gore, M. Dvorak, H.F. Paku, S. Kerbel, R.S. Dome, B. Reynolds, A.R. (2017). Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. J pathol, Vol.241 (3), pp. 362-374.  show abstract  full text

O'Reilly, A. Larkin, J. (2017). Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. Expert rev clin pharmacol, Vol.10 (3), pp. 251-262.  show abstract  full text

Bracarda, S. Negrier, S. Casper, J. Porta, C. Schmidinger, M. Larkin, J. Gross Goupil, M. Escudier, B. (2017). How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. Expert rev anticancer ther, Vol.17 (3), pp. 227-233.  show abstract  full text

Weber, J.S. Hodi, F.S. Wolchok, J.D. Topalian, S.L. Schadendorf, D. Larkin, J. Sznol, M. Long, G.V. Li, H. Waxman, I.M. Jiang, J. Robert, C. (2017). Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J clin oncol, Vol.35 (7), pp. 785-792.  show abstract  full text

Morganstein, D.L. Lai, Z. Spain, L. Diem, S. Levine, D. Mace, C. Gore, M. Larkin, J. (2017). Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin endocrinol (oxf), Vol.86 (4), pp. 614-620.  show abstract  full text

Spain, L. Schmid, T. Gore, M. Larkin, J. (2017). Efficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features. Eur j cancer, Vol.75, pp. 243-244.  full text

Rothermundt, C. von Rappard, J. Eisen, T. Escudier, B. Grünwald, V. Larkin, J. McDermott, D. Oldenburg, J. Porta, C. Rini, B. Schmidinger, M. Sternberg, C.N. Putora, P.M. (2017). Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms. World j urol, Vol.35 (4), pp. 641-648.  show abstract  full text

Wolchok, J.D. Chiarion-Sileni, V. Gonzalez, R. Rutkowski, P. Grob, J.-. Cowey, C.L. Lao, C.D. Wagstaff, J. Schadendorf, D. Ferrucci, P.F. Smylie, M. Dummer, R. Hill, A. Hogg, D. Haanen, J. Carlino, M.S. Bechter, O. Maio, M. Marquez-Rodas, I. Guidoboni, M. McArthur, G. Lebbé, C. Ascierto, P.A. Long, G.V. Cebon, J. Sosman, J. Postow, M.A. Callahan, M.K. Walker, D. Rollin, L. Bhore, R. Hodi, F.S. Larkin, J. (2017). Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N engl j med, Vol.377 (14), pp. 1345-1356.  show abstract  full text

Larkin, J. Chmielowski, B. Lao, C.D. Hodi, F.S. Sharfman, W. Weber, J. Suijkerbuijk, K.P. Azevedo, S. Li, H. Reshef, D. Avila, A. Reardon, D.A. (2017). Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Oncologist, Vol.22 (6), pp. 709-718.  show abstract  full text

Stewart, G.D. Aitchison, M. Bex, A. Larkin, J. Lawless, C. Méjean, A. Nathan, P. Oades, G. Patard, J.-. Paul, J. Ravaud, A. Escudier, B. Renal Cross Channel Group, (2017). Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered. Eur urol, Vol.71 (6), pp. 845-847.  show abstract  full text

O'reilly, A. Larkin, J. (2017). Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. Expert rev anticancer ther, Vol.17 (7), pp. 647-655.  show abstract  full text

Blank, C.U. Larkin, J. Arance, A.M. Hauschild, A. Queirolo, P. Del Vecchio, M. Ascierto, P.A. Krajsova, I. Schachter, J. Neyns, B. Garbe, C. Chiarion Sileni, V. Mandalà, M. Gogas, H. Espinosa, E. Hospers, G.A. Miller, W.H. Robson, S. Makrutzki, M. Antic, V. Brown, M.P. (2017). Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. Eur j cancer, Vol.79, pp. 176-184.  show abstract  full text

Colomba, E. Le Teuff, G. Eisen, T. Stewart, G.D. Fife, K. Larkin, J. Biondo, A. Pickering, L. Srinivasan, A. Boyle, H. Derosa, L. Sternberg, C.N. Recine, F. Ralph, C. Saldana, C. Barthélémy, P. Bernhard, J.C. Gurney, H. Verhoest, G. Vauleon, E. Bigot, P. Berger, J. Pfister, C. Gravis, G. Rodier, J.-. Culine, S. Caty, A. Rolland, F. Priou, F. Escudier, B. Albiges, L. (2017). Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. Eur j cancer, Vol.80, pp. 55-62.  show abstract  full text

Haanen, J.B. Carbonnel, F. Robert, C. Kerr, K.M. Peters, S. Larkin, J. Jordan, K. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, (2017). Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann oncol, Vol.28 Suppl 4, pp. iv119-iv142.  full text

Turajlic, S. Litchfield, K. Xu, H. Rosenthal, R. McGranahan, N. Reading, J.L. Wong, Y.N. Rowan, A. Kanu, N. Al Bakir, M. Chambers, T. Salgado, R. Savas, P. Loi, S. Birkbak, N.J. Sansregret, L. Gore, M. Larkin, J. Quezada, S.A. Swanton, C. (2017). Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet oncol, Vol.18 (8), pp. 1009-1021.  show abstract  full text

Matoori, S. Thian, Y. Koh, D.-. Sohaib, A. Larkin, J. Pickering, L. Gutzeit, A. (2017). Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients. Transl oncol, Vol.10 (4), pp. 679-685.  show abstract  full text

O'Reilly, A. Larkin, J. (2017). The safety of nivolumab for the treatment of metastatic melanoma. Expert opin drug saf, Vol.16 (8), pp. 955-961.  show abstract  full text

Scelo, G. Purdue, M.P. Brown, K.M. Johansson, M. Wang, Z. Eckel-Passow, J.E. Ye, Y. Hofmann, J.N. Choi, J. Foll, M. Gaborieau, V. Machiela, M.J. Colli, L.M. Li, P. Sampson, J.N. Abedi-Ardekani, B. Besse, C. Blanche, H. Boland, A. Burdette, L. Chabrier, A. Durand, G. Le Calvez-Kelm, F. Prokhortchouk, E. Robinot, N. Skryabin, K.G. Wozniak, M.B. Yeager, M. Basta-Jovanovic, G. Dzamic, Z. Foretova, L. Holcatova, I. Janout, V. Mates, D. Mukeriya, A. Rascu, S. Zaridze, D. Bencko, V. Cybulski, C. Fabianova, E. Jinga, V. Lissowska, J. Lubinski, J. Navratilova, M. Rudnai, P. Szeszenia-Dabrowska, N. Benhamou, S. Cancel-Tassin, G. Cussenot, O. Baglietto, L. Boeing, H. Khaw, K.-. Weiderpass, E. Ljungberg, B. Sitaram, R.T. Bruinsma, F. Jordan, S.J. Severi, G. Winship, I. Hveem, K. Vatten, L.J. Fletcher, T. Koppova, K. Larsson, S.C. Wolk, A. Banks, R.E. Selby, P.J. Easton, D.F. Pharoah, P. Andreotti, G. Freeman, L.E. Koutros, S. Albanes, D. Männistö, S. Weinstein, S. Clark, P.E. Edwards, T.L. Lipworth, L. Gapstur, S.M. Stevens, V.L. Carol, H. Freedman, M.L. Pomerantz, M.M. Cho, E. Kraft, P. Preston, M.A. Wilson, K.M. Michael Gaziano, J. Sesso, H.D. Black, A. Freedman, N.D. Huang, W.-. Anema, J.G. Kahnoski, R.J. Lane, B.R. Noyes, S.L. Petillo, D. Teh, B.T. Peters, U. White, E. Anderson, G.L. Johnson, L. Luo, J. Buring, J. Lee, I.-. Chow, W.-. Moore, L.E. Wood, C. Eisen, T. Henrion, M. Larkin, J. Barman, P. Leibovich, B.C. Choueiri, T.K. Mark Lathrop, G. Rothman, N. Deleuze, J.-. McKay, J.D. Parker, A.S. Wu, X. Houlston, R.S. Brennan, P. Chanock, S.J. (2017). Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nat commun, Vol.8, p. 15724.  show abstract  full text

Schadendorf, D. Larkin, J. Wolchok, J. Hodi, F.S. Chiarion-Sileni, V. Gonzalez, R. Rutkowski, P. Grob, J.-. Cowey, C.L. Lao, C. Wagstaff, J. Callahan, M.K. Postow, M.A. Smylie, M. Ferrucci, P.F. Dummer, R. Hill, A. Taylor, F. Sabater, J. Walker, D. Kotapati, S. Abernethy, A. Long, G.V. (2017). Health-related quality of life results from the phase III CheckMate 067 study. Eur j cancer, Vol.82, pp. 80-91.  show abstract  full text

Ugurel, S. Röhmel, J. Ascierto, P.A. Flaherty, K.T. Grob, J.J. Hauschild, A. Larkin, J. Long, G.V. Lorigan, P. McArthur, G.A. Ribas, A. Robert, C. Schadendorf, D. Garbe, C. (2017). Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur j cancer, Vol.83, pp. 247-257.  show abstract  full text

Long, G.V. Hauschild, A. Santinami, M. Atkinson, V. Mandalà, M. Chiarion-Sileni, V. Larkin, J. Nyakas, M. Dutriaux, C. Haydon, A. Robert, C. Mortier, L. Schachter, J. Schadendorf, D. Lesimple, T. Plummer, R. Ji, R. Zhang, P. Mookerjee, B. Legos, J. Kefford, R. Dummer, R. Kirkwood, J.M. (2017). Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N engl j med, Vol.377 (19), pp. 1813-1823.  show abstract  full text

Weber, J. Mandala, M. Del Vecchio, M. Gogas, H.J. Arance, A.M. Cowey, C.L. Dalle, S. Schenker, M. Chiarion-Sileni, V. Marquez-Rodas, I. Grob, J.-. Butler, M.O. Middleton, M.R. Maio, M. Atkinson, V. Queirolo, P. Gonzalez, R. Kudchadkar, R.R. Smylie, M. Meyer, N. Mortier, L. Atkins, M.B. Long, G.V. Bhatia, S. Lebbé, C. Rutkowski, P. Yokota, K. Yamazaki, N. Kim, T.M. de Pril, V. Sabater, J. Qureshi, A. Larkin, J. Ascierto, P.A. CheckMate 238 Collaborators, (2017). Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N engl j med, Vol.377 (19), pp. 1824-1835.  show abstract  full text

Hsieh, J.J. Purdue, M.P. Signoretti, S. Swanton, C. Albiges, L. Schmidinger, M. Heng, D.Y. Larkin, J. Ficarra, V. (2017). Renal cell carcinoma. Nat rev dis primers, Vol.3, p. 17009.  show abstract  full text

Flynn, M.J. Larkin, J.M. (2017). Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. Expert opin pharmacother, Vol.18 (14), pp. 1477-1490.  show abstract  full text

D'Angelo, S.P. Larkin, J. Sosman, J.A. Lebbé, C. Brady, B. Neyns, B. Schmidt, H. Hassel, J.C. Hodi, F.S. Lorigan, P. Savage, K.J. Miller, W.H. Mohr, P. Marquez-Rodas, I. Charles, J. Kaatz, M. Sznol, M. Weber, J.S. Shoushtari, A.N. Ruisi, M. Jiang, J. Wolchok, J.D. (2017). Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. J clin oncol, Vol.35 (2), pp. 226-235.  show abstract  full text

Machiela, M.J. Hofmann, J.N. Carreras-Torres, R. Brown, K.M. Johansson, M. Wang, Z. Foll, M. Li, P. Rothman, N. Savage, S.A. Gaborieau, V. McKay, J.D. Ye, Y. Henrion, M. Bruinsma, F. Jordan, S. Severi, G. Hveem, K. Vatten, L.J. Fletcher, T. Koppova, K. Larsson, S.C. Wolk, A. Banks, R.E. Selby, P.J. Easton, D.F. Pharoah, P. Andreotti, G. Freeman, L.E. Koutros, S. Albanes, D. Mannisto, S. Weinstein, S. Clark, P.E. Edwards, T.E. Lipworth, L. Gapstur, S.M. Stevens, V.L. Carol, H. Freedman, M.L. Pomerantz, M.M. Cho, E. Kraft, P. Preston, M.A. Wilson, K.M. Gaziano, J.M. Sesso, H.S. Black, A. Freedman, N.D. Huang, W.-. Anema, J.G. Kahnoski, R.J. Lane, B.R. Noyes, S.L. Petillo, D. Colli, L.M. Sampson, J.N. Besse, C. Blanche, H. Boland, A. Burdette, L. Prokhortchouk, E. Skryabin, K.G. Yeager, M. Mijuskovic, M. Ognjanovic, M. Foretova, L. Holcatova, I. Janout, V. Mates, D. Mukeriya, A. Rascu, S. Zaridze, D. Bencko, V. Cybulski, C. Fabianova, E. Jinga, V. Lissowska, J. Lubinski, J. Navratilova, M. Rudnai, P. Szeszenia-Dabrowska, N. Benhamou, S. Cancel-Tassin, G. Cussenot, O. Bueno-de-Mesquita, H.B. Canzian, F. Duell, E.J. Ljungberg, B. Sitaram, R.T. Peters, U. White, E. Anderson, G.L. Johnson, L. Luo, J. Buring, J. Lee, I.-. Chow, W.-. Moore, L.E. Wood, C. Eisen, T. Larkin, J. Choueiri, T.K. Lathrop, G.M. Teh, B.T. Deleuze, J.-. Wu, X. Houlston, R.S. Brennan, P. Chanock, S.J. Scelo, G. Purdue, M.P. (2017). Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. Eur urol, Vol.72 (5), pp. 747-754.  show abstract  full text

Bowyer, S. Prithviraj, P. Lorigan, P. Larkin, J. McArthur, G. Atkinson, V. Millward, M. Khou, M. Diem, S. Ramanujam, S. Kong, B. Liniker, E. Guminski, A. Parente, P. Andrews, M.C. Parakh, S. Cebon, J. Long, G.V. Carlino, M.S. Klein, O. (2017). Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''. Br j cancer, Vol.116 (8), p. e15.  full text

Grande, E. Glen, H. Aller, J. Argenziano, G. Lamas, M.J. Ruszniewski, P. Zamorano, J.L. Edmonds, K. Sarker, S. Staehler, M. Larkin, J. (2017). Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma. Expert opin drug saf, Vol.16 (12), pp. 1413-1426.  show abstract  full text

Arce Vargas, F. Furness, A.J. Solomon, I. Joshi, K. Mekkaoui, L. Lesko, M.H. Miranda Rota, E. Dahan, R. Georgiou, A. Sledzinska, A. Ben Aissa, A. Franz, D. Werner Sunderland, M. Wong, Y.N. Henry, J.Y. O'Brien, T. Nicol, D. Challacombe, B. Beers, S.A. Melanoma TRACERx Consortium, Renal TRACERx Consortium, Lung TRACERx Consortium, Turajlic, S. Gore, M. Larkin, J. Swanton, C. Chester, K.A. Pule, M. Ravetch, J.V. Marafioti, T. Peggs, K.S. Quezada, S.A. (2017). Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity, Vol.46 (4), pp. 577-586.  show abstract  full text

Schachter, J. Ribas, A. Long, G.V. Arance, A. Grob, J.-. Mortier, L. Daud, A. Carlino, M.S. McNeil, C. Lotem, M. Larkin, J. Lorigan, P. Neyns, B. Blank, C. Petrella, T.M. Hamid, O. Zhou, H. Ebbinghaus, S. Ibrahim, N. Robert, C. (2017). Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet, Vol.390 (10105), pp. 1853-1862.  show abstract  full text

Wolchok, J.D. Rollin, L. Larkin, J. (2017). Nivolumab and Ipilimumab in Advanced Melanoma. N engl j med, Vol.377 (25), pp. 2503-2504.  full text

de la Cruz-Merino, L. Di Guardo, L. Grob, J.-. Venosa, A. Larkin, J. McArthur, G.A. Ribas, A. Ascierto, P.A. Evans, J.T. Gomez-Escobar, A. Barteselli, G. Eng, S. Hsu, J.J. Uyei, A. Dréno, B. (2017). Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. J transl med, Vol.15 (1), p. 146.  show abstract  full text

Seifert, H. Hirata, E. Gore, M. Khabra, K. Messiou, C. Larkin, J. Sahai, E. (2016). Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases. Pigment cell melanoma res, Vol.29 (1), pp. 92-100.  show abstract

Bridgeman, V.L. Wan, E. Foo, S. Nathan, M.R. Welti, J.C. Frentzas, S. Vermeulen, P.B. Preece, N. Springer, C.J. Powles, T. Nathan, P.D. Larkin, J. Gore, M. Vasudev, N.S. Reynolds, A.R. (2016). Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. Mol cancer ther, Vol.15 (1), pp. 172-183.  show abstract  full text

Ugurel, S. Röhmel, J. Ascierto, P.A. Flaherty, K.T. Grob, J.J. Hauschild, A. Larkin, J. Long, G.V. Lorigan, P. McArthur, G.A. Ribas, A. Robert, C. Schadendorf, D. Garbe, C. (2016). Survival of patients with advanced metastatic melanoma: The impact of novel therapies. Eur j cancer, Vol.53, pp. 125-134.  show abstract

Motzer, R.J. Hutson, T.E. Ren, M. Dutcus, C. Larkin, J. (2016). Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet oncol, Vol.17 (1), pp. e4-e5.

Diem, S. Kasenda, B. Spain, L. Martin-Liberal, J. Marconcini, R. Gore, M. Larkin, J. (2016). Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br j cancer, Vol.114 (3), pp. 256-261.  show abstract

Porta, C. Tortora, G. Larkin, J.M. Hutson, T.E. (2016). Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions. Future oncol, Vol.12 (4), pp. 533-549.  show abstract

Spain, L. Diem, S. Larkin, J. (2016). Management of toxicities of immune checkpoint inhibitors. Cancer treat rev, Vol.44, pp. 51-60.  show abstract

Thomas, C.L. Mortimer, P.S. Larkin, J.M. Basu, T.N. Gore, M.E. Fearfield, L. (2016). A mitogen-activated protein kinase kinase inhibitor induced compound skin toxicity with oedema in metastatic malignant melanoma. Clin exp dermatol, Vol.41 (3), pp. 267-271.  show abstract

Seifert, H. Fisher, R. Martin-Liberal, J. Edmonds, K. Hughes, P. Khabra, K. Gore, M. Larkin, J. (2016). Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib. Melanoma res, Vol.26 (2), pp. 138-144.  show abstract  full text

Gravis, G. Chanez, B. Derosa, L. Beuselinck, B. Barthelemy, P. Laguerre, B. Brachet, P.-. Joly, F. Escudier, B. Harrison, D.J. Laird, A. Vasudev, N. Ralph, C. Larkin, J. Lote, H. Salem, N. Walz, J. Thomassin, J. Sfumato, P. Stewart, G.D. Boher, J.M. Renal Cross Channel Group, (2016). Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. Urol oncol, Vol.34 (4), pp. 167.e17-167.e23.  show abstract  full text

Powles, T. Brown, J. Larkin, J. Jones, R. Ralph, C. Hawkins, R. Chowdhury, S. Boleti, E. Bhal, A. Fife, K. Webb, A. Crabb, S. Geldart, T. Hill, R. Dunlop, J. Hall, P.E. McLaren, D. Ackerman, C. Beltran, L. Nathan, P. (2016). A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Ann oncol, Vol.27 (5), pp. 880-886.  show abstract

Spain, L. Higgins, R. Gopalakrishnan, K. Turajlic, S. Gore, M. Larkin, J. (2016). Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann oncol, Vol.27 (6), pp. 1135-1137.  show abstract

Atkins, M.B. Larkin, J. (2016). Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. J natl cancer inst, Vol.108 (6), p. djv414.  show abstract

Spain, L. Larkin, J. Martin-Liberal, J. (2016). Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome". Cancer immunol immunother, Vol.65 (6), pp. 769-770.  full text

Spain, L. Larkin, J. (2016). Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma. Immunotherapy, Vol.8 (6), pp. 677-679.  full text

Rini, B.I. Dorff, T.B. Elson, P. Rodriguez, C.S. Shepard, D. Wood, L. Humbert, J. Pyle, L. Wong, Y.-. Finke, J.H. Rayman, P.A. Larkin, J.M. Garcia, J.A. Plimack, E.R. (2016). Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet oncol, Vol.17 (9), pp. 1317-1324.  show abstract  full text

Ascierto, P.A. McArthur, G.A. Dréno, B. Atkinson, V. Liszkay, G. Di Giacomo, A.M. Mandalà, M. Demidov, L. Stroyakovskiy, D. Thomas, L. de la Cruz-Merino, L. Dutriaux, C. Garbe, C. Yan, Y. Wongchenko, M. Chang, I. Hsu, J.J. Koralek, D.O. Rooney, I. Ribas, A. Larkin, J. (2016). Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet oncol, Vol.17 (9), pp. 1248-1260.  show abstract  full text

Bowyer, S. Prithviraj, P. Lorigan, P. Larkin, J. McArthur, G. Atkinson, V. Millward, M. Khou, M. Diem, S. Ramanujam, S. Kong, B. Liniker, E. Guminski, A. Parente, P. Andrews, M.C. Parakh, S. Cebon, J. Long, G.V. Carlino, M.S. Klein, O. (2016). Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br j cancer, Vol.114 (10), pp. 1084-1089.  show abstract  full text

Spain, L. Goode, E. McGovern, Y. Joshi, K. Larkin, J. (2016). The combination of vemurafenib and cobimetinib in advanced melanoma. Expert opinion on orphan drugs, Vol.4 (11), pp. 1105-1111.  full text

Turajlic, S. Larkin, J. (2016). Systemic treatment of advanced papillary renal cell carcinoma: Where next?. Eur j cancer, Vol.69, pp. 223-225.  full text

Nanda, V.G. Peng, W. Hwu, P. Davies, M.A. Ciliberto, G. Fattore, L. Malpicci, D. Aurisicchio, L. Ascierto, P.A. Croce, C.M. Mancini, R. Spranger, S. Gajewski, T.F. Wang, Y. Ferrone, S. Vanpouille-Box, C. Wennerberg, E. Pilones, K.A. Formenti, S.C. Demaria, S. Tang, H. Wang, Y. Fu, Y.-. Dummer, R. Puzanov, I. Tarhini, A. Chauvin, J.-. Pagliano, O. Fourcade, J. Sun, Z. Wang, H. Sanders, C. Kirkwood, J.M. Chen, T.-. Maurer, M. Korman, A.J. Zarour, H.M. Stroncek, D.F. Huber, V. Rivoltini, L. Thurin, M. Rau, T. Lugli, A. Pagès, F. Camarero, J. Sancho, A. Jommi, C. de Coaña, Y.P. Wolodarski, M. Yoshimoto, Y. Gentilcore, G. Poschke, I. Masucci, G.V. Hansson, J. Kiessling, R. Scognamiglio, G. Sabbatino, F. Marino, F.Z. Anniciello, A.M. Cantile, M. Cerrone, M. Scala, S. D’alterio, C. Ianaro, A. Cirin, G. Liguori, G. Bott, G. Chapman, P.B. Robert, C. Larkin, J. Haanen, J.B. Ribas, A. Hogg, D. Hamid, O. Testori, A. Lorigan, P. Sosman, J.A. Flaherty, K.T. Yue, H. Coleman, S. Caro, I. Hauschild, A. McArthur, G.A. Sznol, M. Callahan, M.K. Kluger, H. Postow, M.A. Gordan, R. Segal, N.H. Rizvi, N.A. Lesokhin, A. Atkins, M.B. Burke, M.M. Ralabate, A. Rivera, A. Kronenberg, S.A. Agunwamba, B. Ruisi, M. Horak, C. Jiang, J. Wolchok, J. Ascierto, P.A. Liszkay, G. Maio, M. Mandalà, M. Demidov, L. Stoyakovskiy, D. Thomas, L. de la Cruz-Merino, L. Atkinson, V. Dutriaux, C. Garbe, C. Wongchenko, M. Chang, I. Koralek, D.O. Rooney, I. Yan, Y. Dréno, B. Sullivan, R. Patel, M. Hodi, S. Amaria, R. Boasberg, P. Wallin, J. He, X. Cha, E. Richie, N. Ballinger, M. Smith, D.C. Bauer, T.M. Wasser, J.S. Luke, J.J. Balmanoukian, A.S. Kaufman, D.R. Zhao, Y. Maleski, J. Leopold, L. Gangadhar, T.C. Long, G.V. Michielin, O. VanderWalde, A. Andtbacka, R.H. Cebon, J. Fernandez, E. Malvehy, J. Olszanski, A.J. Gause, C. Chen, L. Chou, J. Stephen Hodi, F. Brady, B. Mortier, L. Hassel, J.C. Rutkowski, P. McNeil, C. Kalinka-Warzocha, E. Lebbé, C. Ny, L. Chacon, M. Queirolo, P. Loquai, C. Cheema, P. Berrocal, A. Eizmendi, K.M. Bar-Sela, G. Horak, C. Hardy, H. Weber, J.S. Grob, J.-. Marquez-Rodas, I. Schmidt, H. Briscoe, K. Baurain, J.-. Wolchok, J.D. Pinto, R. De Summa, S. Garrisi, V.M. Strippoli, S. Azzariti, A. Guida, G. Guida, M. Tommasi, S. Jacquelot, N. Enot, D. Flament, C. Pitt, J.M. Vimond, N. Blattner, C. Yamazaki, T. Roberti, M.-. Vetizou, M. Daillere, R. Poirier-Colame, V. la Semeraro, M. Caignard, A. Slingluff, C.L. Sallusto, F. Rusakiewicz, S. Weide, B. Marabelle, A. Kohrt, H. Dalle, S. Cavalcanti, A. Kroemer, G. Di Giacomo, A.M. Maio, M. Wong, P. Yuan, J. Umansky, V. Eggermont, A. Zitvogel, L. Anna, P. Marco, T. Stefania, S. Francesco, M. Mariaelena, C. Gabriele, M. Antonio, A.P. Franco, S. Roberti, M.P. Enot, D.P. Semeraro, M. Jégou, S. Flores, C. Chen, T.-. Kwon, B.S. Anderson, A.C. Borg, C. Aubin, F. Ayyoub, M. De Presbiteris, A.L. Cordaro, F.G. Camerlingo, R. Fratangelo, F. Mozzillo, N. Pirozzi, G. Patriarca, E.J. Caputo, E. Motti, M.L. Falcon, R. Miceli, R. Capone, M. Madonna, G. Mallardo, D. Carrier, M.V. Panza, E. De Cicco, P. Armogida, C. Ercolano, G. Botti, G. Cirino, G. Sandru, A. Blank, M. Balatoni, T. Olasz, J. Farkas, E. Szollar, A. Savolt, A. Godeny, M. Csuka, O. Horvath, S. Eles, K. Shoenfeld, Y. Kasler, M. Costantini, S. Capone, F. Moradi, F. Berglund, P. Leandersson, K. Linnskog, R. Andersson, T. Prasad, C.P. Nigro, C.L. Lattanzio, L. Wang, H. Proby, C. Syed, N. Occelli, M. Cauchi, C. Merlano, M. Harwood, C. Thompson, A. Crook, T. Bifulco, K. Ingangi, V. Minopoli, M. Ragone, C. Pessi, A. Mannavola, F. D’Oronzo, S. Felici, C. Tucci, M. Doronzo, A. Silvestris, F. Ferretta, A. Guida, S. Maida, I. Cocco, T. Passarelli, A. Quaresmini, D. Franzese, O. Palermo, B. Di Donna, C. Sperduti, I. Foddai, M. Stabile, H. Gismondi, A. Santoni, A. Nisticò, P. Sponghini, A.P. Platini, F. Marra, E. Rondonotti, D. Alabiso, O. Fierro, M.T. Savoia, P. Stratica, F. Quaglino, P. Di Monta, G. Corrado, C. Di Marzo, M. Ugo, M. Di Cecilia, M.L. Nicola, M. Fusciello, C. Marra, A. Guarrasi, R. Baldi, C. Russo, R. Di Giulio, G. Faiola, V. Zeppa, P. Pepe, S. Gambale, E. Carella, C. Di Paolo, A. De Tursi, M. Marra, L. De Murtas, F. Sorrentino, V. Voinea, S. Panaitescu, E. Bolovan, M. Stanciu, A. Cinca, S. Botti, C. Aquino, G. Anniciello, A. Fortes, C. Mastroeni, S. Caggiati, A. Passarelli, F. Zappalà, A. Capuano, M. Bono, R. Nudo, M. Marino, C. Michelozzi, P. De Biasio, V. Battarra, V.C. Formenti, S. Ascierto, M.L. McMiller, T.L. Berger, A.E. Danilova, L. Anders, R.A. Netto, G.J. Xu, H. Pritchard, T.S. Fan, J. Cheadle, C. Cope, L. Drake, C.G. Pardoll, D.M. Taube, J.M. Topalian, S.L. Gnjatic, S. Nataraj, S. Imai, N. Rahman, A. Jungbluth, A.A. Pan, L. Venhaus, R. Park, A. Lehmann, F.F. Lendvai, N. Cohen, A.D. Cho, H.J. Daniel, S. Hirsh, V. (2016). Melanoma and immunotherapy bridge 2015 : Naples, Italy 1-5 December 2015. J transl med, Vol.14 (1), p. 65.  show abstract

Spain, L. Julve, M. Larkin, J. (2016). Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations. Expert opin pharmacother, Vol.17 (7), pp. 1031-1038.  show abstract

Spain, L. Larkin, J. (2016). Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Expert opin biol ther, Vol.16 (3), pp. 389-396.  show abstract

Long, G.V. Stroyakovskiy, D. Gogas, H. Levchenko, E. de Braud, F. Larkin, J. Garbe, C. Jouary, T. Hauschild, A. Grob, J.-. Chiarion-Sileni, V. Lebbe, C. Mandalà, M. Millward, M. Arance, A. Bondarenko, I. Haanen, J.B. Hansson, J. Utikal, J. Ferraresi, V. Kovalenko, N. Mohr, P. Probachai, V. Schadendorf, D. Nathan, P. Robert, C. Ribas, A. DeMarini, D.J. Irani, J.G. Swann, S. Legos, J.J. Jin, F. Mookerjee, B. Flaherty, K. (2015). Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet, Vol.386 (9992), pp. 444-451.  show abstract

Lorigan, P. Ascierto, P.A. Dummer, R. Eggermont, A.M. Flaherty, K.T. Garbe, C. Gogas, H. Hauschild, A. Kefford, R.F. Kirkwood, J.M. Larkin, J. Long, G.V. Maio, M. McArthur, G.A. Ribas, A. Robert, C. Schadendorf, D. Sondak, V.K. Wolchok, J.D. Hudson, A.M. (2015). Expanded access programmes: patient interests versus clinical trial integrity. Lancet oncology, Vol.16 (1), pp. 15-17.

Coupe, N. Corrie, P. Hategan, M. Larkin, J. Gore, M. Gupta, A. Wise, A. Suter, S. Ciria, C. Love, S. Collins, L. Middleton, M.R. (2015). PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. Eur j cancer, Vol.51 (3), pp. 359-366.  show abstract

Wilkins, A. Furness, A. Corbett, R.W. Bloomfield, A. Porta, N. Morris, S. Ali, Z. Larkin, J. Harrington, K. (2015). The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma. Br j cancer, Vol.113 (9), pp. 1275-1281.  show abstract  full text

Turajlic, S. Larkin, J. Swanton, C. (2015). SnapShot: Renal Cell Carcinoma. Cell, Vol.163 (6), pp. 1556-1556.e1.  show abstract

Sinha, R. Larkin, J. Fearfield, L. (2015). Clinical resolution of vemurafenib-induced squamous cell carcinoma with topical 5-fluorouracil. Br j dermatol, Vol.172 (4), pp. 1135-1136.

Weber, J.S. D'Angelo, S.P. Minor, D. Hodi, F.S. Gutzmer, R. Neyns, B. Hoeller, C. Khushalani, N.I. Miller, W.H. Lao, C.D. Linette, G.P. Thomas, L. Lorigan, P. Grossmann, K.F. Hassel, J.C. Maio, M. Sznol, M. Ascierto, P.A. Mohr, P. Chmielowski, B. Bryce, A. Svane, I.M. Grob, J.-. Krackhardt, A.M. Horak, C. Lambert, A. Yang, A.S. Larkin, J. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet oncol, Vol.16 (4), pp. 375-384.  show abstract

Thomas, C.L. Mortimer, P.S. Larkin, J.M. Basu, T.N. Gore, M.E. Fearfield, L. (2015). MEK-inhibitor induced compound skin toxicity with oedema in metastatic malignant melanoma: a case series. Australasian journal of dermatology, Vol.56, pp. 78-78.

Motzer, R.J. Escudier, B. McDermott, D.F. George, S. Hammers, H.J. Srinivas, S. Tykodi, S.S. Sosman, J.A. Procopio, G. Plimack, E.R. Castellano, D. Choueiri, T.K. Gurney, H. Donskov, F. Bono, P. Wagstaff, J. Gauler, T.C. Ueda, T. Tomita, Y. Schutz, F.A. Kollmannsberger, C. Larkin, J. Ravaud, A. Simon, J.S. Xu, L.-. Waxman, I.M. Sharma, P. CheckMate 025 Investigators, (2015). Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N engl j med, Vol.373 (19), pp. 1803-1813.  show abstract

Schadendorf, D. Amonkar, M.M. Stroyakovskiy, D. Levchenko, E. Gogas, H. de Braud, F. Grob, J.-. Bondarenko, I. Garbe, C. Lebbe, C. Larkin, J. Chiarion-Sileni, V. Millward, M. Arance, A. Mandalà, M. Flaherty, K.T. Nathan, P. Ribas, A. Robert, C. Casey, M. DeMarini, D.J. Irani, J.G. Aktan, G. Long, G.V. (2015). Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur j cancer, Vol.51 (7), pp. 833-840.  show abstract

Yousaf, N. Davidson, M. Goode, E. Thomas, C. Hung, R. Gore, M. Larkin, J. (2015). The cost of ipilimumab toxicity: a single-centre analysis. Melanoma res, Vol.25 (3), pp. 259-264.  show abstract

Pickering, L.M. Larkin, J. (2015). Kidney cancer: Carbonic anhydrase IX in resected clear cell RCC. Nat rev urol, Vol.12 (6), pp. 309-310.

Richman, J. Martin-Liberal, J. Diem, S. Larkin, J. (2015). BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Expert opin pharmacother, Vol.16 (9), pp. 1285-1297.  show abstract

Martin-Liberal, J. Kordbacheh, T. Larkin, J. (2015). Safety of pembrolizumab for the treatment of melanoma. Expert opin drug saf, Vol.14 (6), pp. 957-964.  show abstract

Martin-Liberal, J. Furness, A.J. Joshi, K. Peggs, K.S. Quezada, S.A. Larkin, J. (2015). Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer immunol immunother, Vol.64 (6), pp. 765-767.  show abstract

Larkin, J. Lao, C.D. Urba, W.J. McDermott, D.F. Horak, C. Jiang, J. Wolchok, J.D. (2015). Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. Jama oncol, Vol.1 (4), pp. 433-440.  show abstract

Gulati, S. Turajlic, S. Larkin, J. Bates, P.A. Swanton, C. (2015). Relapse models for clear cell renal carcinoma. Lancet oncol, Vol.16 (8), pp. e376-e378.

Wolchok, J.D. Chiarion-Sileni, V. Gonzalez, R. Rutkowski, P. Grob, J.J. Cowey, C.L. Lao, C.D. Schadendorf, D. Ferrucci, P.F. Smylie, M. Dummer, R. Hill, A. Haanen, J. Maio, M. McArthur, G. Yang, A. Rollin, L. Horak, C. Larkin, J. Hodi, F.S. (2015). CHECKMATE 067: A PHASE III RANDOMIZED DOUBLE-BLIND STUDY OF NIVOLUMAB (NIVO) MONOTHERAPY OR NIVO COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI MONOTHERAPY IN PREVIOUSLY UNTREATED PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL). Asia-pacific journal of clinical oncology, Vol.11, pp. 68-68.

Soultati, A. Stares, M. Swanton, C. Larkin, J. Turajlic, S. (2015). How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?. Curr opin urol, Vol.25 (5), pp. 358-366.  show abstract

Rothermundt, C. Bailey, A. Cerbone, L. Eisen, T. Escudier, B. Gillessen, S. Grünwald, V. Larkin, J. McDermott, D. Oldenburg, J. Porta, C. Rini, B. Schmidinger, M. Sternberg, C. Putora, P.M. (2015). Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes. Oncologist, Vol.20 (9), pp. 1028-1035.  show abstract

Moriceau, G. Hugo, W. Hong, A. Shi, H. Kong, X. Yu, C.C. Koya, R.C. Samatar, A.A. Khanlou, N. Braun, J. Ruchalski, K. Seifert, H. Larkin, J. Dahlman, K.B. Johnson, D.B. Algazi, A. Sosman, J.A. Ribas, A. Lo, R.S. (2015). Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer cell, Vol.27 (2), pp. 240-256.  show abstract

Sinha, R. Larkin, J. Gore, M. Fearfield, L. (2015). Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations. Br j dermatol, Vol.173 (4), pp. 1024-1031.  show abstract